Author index*

A

Abdelmouttaleb I, Danchin N, Ilardo C, Aimone-Gastin I, Angioï M, Lozniewski A, Loubinoux J, Le Faou A, Guéant J-L. C-reactive protein and coronary artery disease: additional evidence of the implication of an inflammatory process in acute coronary syndromes. 1999;137:346-51
Abi-Samra F (*see* Burnett et al). 1999;137:435-8
Abramson E (*see* Mazur et al). 1999;137:104-8
Adler Y (*see* Shapira et al). 1999;137:721-5
Aerts AJJ, Dendale P. Nitrate-stimulated tilt test. 1999;137:575 (Letter)
Aguirre FV (*see* Kern et al). 1999;137:1129-36
Aharonian V (*see* Tobis et al). 1999;137:241-9
Ahmad M. Coronary stents: a health system perspective. 1999;137:S142-S144
Aimone-Gastin I (*see* Abdelmouttaleb et al). 1999;137:346-51
Akaishi M (*see* Yoshikawa et al). 1999;137:666-71
Akkaya V (*see* Özcan et al). 1999;137:375-6 (Letter)
Albano M (*see* Johnson et al). 1999;137:1137–44
Alexander JH, Kong DF. Highlights from the 71st American Heart Association Scientific Sessions: November 8 to 11, 1998. 1999;137:555-74
Alexander JH, Kong DF. Session highlights from the European Society of Cardiology XXth Annual Congress: August 22 to 26, 1998. 1999;137:180-6
Alexander JH (*see* Sadowski et al). 1999;137:792-8
Alexander JH, Granger CB, Sadowski Z, Aylward PE, White HD, Thompson TD, Califf RM, Topol EJ. Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials. 1999;137:799-805
Alexander M, Grumbach K, Remy L, Rowell R, Massie BM. Congestive heart failure hospitalizations and survival in California: patterns according to race/ethnicity. 1999;137:919-27
Alloggiamento T, Cummings SR, Redberg RF. Do cardiologists and general internists differ in testing and treating patients with aortic stenosis or mitral regurgitation? A preliminary study with editorial perspective. 1999;137:596-600 (Editorial)
Amanullah AM (*see* Kang et al). 1999;137:949-57
Amende I (*see* Blessing et al). 1999;137:368-71
Amigo M-C (*see* Espínola-Zavaleta et al). 1999;137:974-9
Anderson KA, Bala MV, Weisman HF. An industry perspective on health economics studies. 1999;137:S129-S132
Anderson JL, Prystowsky EN. Sotalol: an important new antiarrhythmic. 1999;137:388-409 (Prog. cardiol.)
Angioï M (*see* Abdelmouttaleb et al). 1999;137:346-51
Antman EM (*see* Gibson et al). 1999;137:1179-84
Antman EM (*see* Kizer et al). 1999;137:79-92
Antman EM (*see* Tanasijevic and Antman). 1999;137:203-6 (Editorial)
Apple FS (*see* Falahati et al). 1999;137:332-7
Arakaki Y (*see* Ohuchi et al). 1999;137:1185-1194
Ardissino D (*see* Kleiman et al). 1999;137:12-23
Arheart K (*see* Ballal et al). 1999;137:469-75
Armstrong G (*see* Leung et al). 1999;137:427-34
Armstrong P (*see* Kleiman et al). 1999;137:12-23
Arumanayagam M (*see* Sanderson et al). 1999;137:653-7
Asinger RW (*see* Dittrich et al). 1999;137:494-9
Assayag P (*see* Benamer et al). 1999;137:815-20
Aubry P (*see* Benamer et al). 1999;137:815-20
Aylward PE (*see* Alexander et al). 1999;137:799-805
Azuma A (*see* Hirasaki et al). 1999;137:109-17

B

Baba A (*see* Yoshikawa et al). 1999;137:666-71
Baccos D (*see* Ottani et al). 1999;137:284-91
Bach JR (*see* Ishikawa et al). 1999;137:895-902
Bach RG (*see* Kern et al). 1999;137:1129-36
Bahler RC (*see* Finkelhor et al). 1999;137:1088-93
Bahlo M (*see* Nägele et al). 1999;137:1044-9
Baker B (*see* Shapiro et al). 1999;137:1100-6
Bala MV (*see* Anderson et al). 1999;137:S129-S132
Ball SP (*see* Becker et al). 1999;137:59-71
Ballal RS, Kapadia S, Secknus M-A, Rubin D, Arheart K, Marwick TH. Prognosis of patients with vascular disease after clinical evaluation and dobutamine stress echocardiography. 1999;137:469-75
Banasiak W (*see* Piepoli et al). 1999;137:1050-6
Bär FW (*see* Ophuis et al). 1999;137:846-53
Barbeau GR. Reuse of coronary catheters: old questions, new environment. 1999;137:1010-1 (Editorial)
Barlera S (*see* Villella et al). 1999;137:443-52
Bartoletti A. (*see* Del Rosso and Bartoletti). 1999;137:575-6 (Letter reply)
Basaran Y (*see* Genchay et al). 1999;137:463-8
Basu S (*see* Senior et al). 1999;137:646-52
Batchelor WB (*see* Peterson and Batchelor). 1999;137:585-7 (Editorial)
Bates ER (*see* Mehta and Bates). 1999;137:603-11
Bates ER (*see* Werns and Bates). 1999;137:213-15 (Editorial)
Baumbach A (*see* Haase et al). 1999;137:234-40
Bavishi N (*see* Rios et al). 1999;137:1057-61
Baxley WA (*see* Liu et al). 1999;137:292-7
Bay W (*see* Fischer et al). 1999;137:162-8
Bazzino O, Díaz R, Tajer C, Paviotti C, Mele E, Trivi M, Piombo A, Hirschson Prado A, Paolasso E. Clinical predictors of in-hospital prognosis in unstable angina: ECLA 3. 1999;137:322-31
Beanlands R (*see* Fallen et al). 1999;137:863-9
Becker RC, Ball SP, Eisenberg P, Borzak S, Held AC, Spencer F, Voyce SJ, Jesse R, Hendel R, Yunsheng M, Hurley T, Hebert J. A randomized multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease. 1999;137:59-71
Benamer H, Steg PG, Benessiano J, Vicaut E, Gaultier CJ, Aubry P, Boudvillain O, Sarfati L, Brochet E, Feldman LJ, Himbert D, Juliard J-M, Assayag P. Elevated cardiac troponin I predicts a high-risk angiographic anatomy of the culprit lesion in unstable angina. 1999;137:815-20
Benessiano J (*see* Benamer et al). 1999;137:815-20
Beppu S (*see* Kawaguchi et al). 1999;137:410-18
Berdan LG (*see* Harrington et al). 1999;137:227-33
Berioli S (*see* Van de Werf et al). 1999;137:786-91
Berman DS (*see* Kang et al). 1999;137:949-57
Betocchi S (*see* Losi et al). 1999;137:968-73
Betriu A (*see* Hasdai et al). 1999;137:612-20
Bezai M (*see* Johnson et al). 1999;137:1137–44
Bhat G (*see* Lenihan et al). 1999;137:942-8
Bie P (*see* Galatius et al). 1999;137:549-54
Blessing E, Hausmann D, Matthias S, Wolpers H-G, Amende I, Mügge A. Intravascular ultrasound and stent implantation: intraobserver and interobserver variability. 1999;137:368-71
Bloch DA (*see* Hornberger et al). 1999;137:1153-1162
Bluhmki E (*see* Van de Werf et al). 1999;137:786-91
Boccuzzi SJ. Angiotensin-converting enzyme inhibitors in the management of congestive heart failure: a pharmaceutical industry perspective. 1999;137:S120-S122
Bodí V, Sanchis J, Llàcer A, Insa L, Chorro FJ, López-Merino V. ST-segment elevation on Q leads at rest and during exercise: relation with myocardial viability and left ventricular remodeling within the first 6 months after infarction. 1999;137:1107-15
Boechler M (*see* Flaker et al). 1999;137:307-12
Bogers AJJC (*see* Dall'Agata et al). 1999;137:1175-81

*January, pp. 1-186; February, pp. 187-376; March, pp. 377-576; April, part 1, pp. 577-768; part 2, pp. S1-S34; May, part 1, pp. 769-978; part 2, pp. S135-S144; June, pp. 979-1194.

Böhm BO (*see* Winkelmann et al). 1999;137:698-705
Bojic M (*see* Nešković et al). 1999;137:361-7
Borggrefe M (*see* Ladwig et al). 1999;137:528-34
Borzak B (*see* Becker et al). 1999;137:59-71
Borzak S, Joseph C, Havstad S, Tilley B, Smith ST, Housholder SD, Gheorghiade M. Lower thrombolytic use for African Americans with myocardial infarction: an influence of clinical presentation? 1999;137:338-45
Bosi S (*see* Ottani et al). 1999;137:284-91
Boudvillain O (*see* Benamer et al). 1999;137:815-20
Boyko WL Jr, Glick HA, Schulman KA. ACE inhibitors in the management of congestive heart failure: comparative economic data. 1999;137:S115-S119
Bradley WA (see Malenka et al). 1999;137:632-8
Bradley WA (see Wennberg et al). 1999;137:639-45
Braunwald E (see Van de Werf et al). 1999;137:786-91
Brazaitis M (see O'Malley et al). 1999;137:932-41
Breburda CSM (see Dall'Agata et al). 1999;137:1175-81
Breithardt G (see Ladwig et al). 1999;137:528-34
Brennessel D (see Chen et al). 1999;137:516-21
Brezynski D (see Ragosta et al). 1999;137:250-7
Briguori C (see Losi et al). 1999;137:968-73
Brochet E (see Benamer et al). 1999;137:815-20
Brodie BR. Why is mortality rate after percutaneous transluminal coronary angioplasty higher in women? 1999;137:582-4 (Editorial)
Brown DL. Disparate effects of the 1989 Loma Prieta and 1994 Northridge earthquakes on hospital admissions for acute myocardial infarction: importance of superimposition of triggers. 1999;137:830-6
Browning R (see Tobis et al). 1999;137:241-9
Bruining N, Sabaté M, Serruys PW. Clinical implications of intravascular ultrasound imaging for stenting procedures. 1999;137:207-10 (Editorial)
Brunnhage C (see Gardtman et al). 1999;137:821-9
Buckalew V (see Neutel et al). 1999;137:118-25
Buist AS (see Istvan et al). 1999;137:928-31
Burnett D, Abi-Samra F, Vacek JL. Use of intravenous adenosine as a noninvasive diagnostic test for sick sinus syndrome. 1999;137:435-8
Burton BK (see Rios et al). 1999;137:1057-61
Burwinkel P (see Lenihan et al). 1999;137:942-8
Butnaru A (see Tzivoni and Butnaru). 1999;137:996-999 (Editorial)

C

Califf RM. Evaluating the economic implications of cardiovascular therapeutics. 1999;137:S35-S37
Califf RM, Mark DB. Dealing with success at the American Heart Journal. 1999;137:769 (Editorial)
Califf RM, Stump D, Topol EJ, Mark DB. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy. 1999;137:S90-S93
Califf RM. What to do with acute atrial fibrillation? 1999;137:601-2 (Editorial)
Califf RM (*see* Alexander et al). 1999;137:799-805
Califf RM (*see* Harrington et al). 1999;137:227-33
Califf RM (*see* Hasdai et al). 1999;137:612-20
Califf RM (*see* Kleiman et al). 1999;137:12-23
Califf RM (*see* Thel et al). 1999;137:264-73
Calmenares-Galvis T (*see* Espínola-Zavaleta et al). 1999;137:974-9
Calvin JE, Klein LW. Defining risk in unstable angina: current trial design does not tell us who should be treated and with what therapy. 1999;137:199-202 (Editorial)
Cambou J-P (*see* Vaur et al). 1999;137:49-58
Cannon CP. Timely thrombolysis: synergism to open arteries and reduce mortality rates. 1999;137:1-3 (Editorial)
Cannon CP (*see* Gibson et al). 1999;137:1179-1184
Cannon CP (*see* Kizer et al). 1999;137:79-92
Canon CP (*see* Van de Werf et al). 1999;137:786-91
Capucci A (*see* Piepoli et al). 1999;137:1050-6
Caracciolo EA (*see* Kern et al). 1999;137:1129-36
Carney RM (*see* Sheps et al). 1999;137:386-7 (Editorial)
Casanova JM (*see* Salazar et al). 1999;137:714-20
Chado H (*see* Ohuchi et al). 1999;137:1185-1194
Chan H-L (*see* Lin et al). 1999;137:658-65
Chen C, Vlasses PH. Consortium perspective: what constitutes a useful economic study? 1999;137:S71-S74
Chen Y, Brennessel D, Walters J, Johnson M, Rosner F, Raza M. Human immunodeficiency virus–associated pericardial effusion: report of 40 cases and review of the literature. 1999;137:516-21
Chen Y-T (*see* Nohria et al). 1999;137:1028-34
Cheng A (*see* Frishman and Cheng). 1999;137:S25-S34
Cheng TO. Acronyms of clinical trials in cardiology—1998. 1999;137:726-65
Cherchi A (*see* Mercuro et al). 1999;137:692-7
Chiariello M (*see* Losi et al). 1999;137:968-73
Ching E (*see* Pinski et al). 1999;137:439-42
Chirakal R (*see* Fallen et al). 1999;137:863-9
Chorro FJ (*see* Bodí et al). 1999;137:1107-15
Christensen D (*see* Falahati et al). 1999;137:332-7
Christensen PD (*see* Norgaard et al). 1999;137:1062-1069
Christiansen EH (*see* Norgaard et al). 1999;137:1062-1069
Chrysant SG V (*see* Neutel et al). 1999;137:118-25
Ciampi Q (*see* Losi et al). 1999;137:968-73
Clark AL (*see* Piepoli et al). 1999;137:1050-6
Clark WA (*see* Rios et al). 1999;137:1057-61
Clemmensen P (*see* Holmvang et al). 1999;137:24-33
Coates AJS (*see* Piepoli et al). 1999;137:1050-6
Coates G (*see* Fallen et al). 1999;137:863-9
Cobb LA (*see* Peckova et al). 1999;137:512-15
Cohen DJ. Evaluation of the cost-effectiveness of coronary stenting: a societal perspective. 1999;137:S133-S137
Cohen EA, Young W, Slaughter PM, Oh P, Naylor CD. Trends in clinical and economic outcomes of coronary angioplasty from 1992 to 1995: a population-based analysis. 1999;137:1012-8
Cohen DJ, Dauerman HL. Treatment of diffuse coronary lesions: a time for randomized trials. 1999;137:193-5 (Editorial)
Col J (*see* Hochman et al). 1999;137:313-21
Coleman RB (*see* Hughes et al). 1999;137:1163-8
Connett JE (*see* Istvan et al). 1999;137:928-31
Cook EF (*see* Johnson et al). 1999;137:1137-44
Cooper RS (*see* Liao et al). 1999;137:837-45
Criger DA (*see* Hasdai et al). 1999;137:612-20
Croft JB (*see* Haldeman et al). 1999;137:352-60
Cromme-Dijkhuis AH (*see* Dall'Agata et al). 1999;137:1175-81
Cruz-Cruz F (*see* Espínola-Zavaleta et al). 1999;137:974-9
Cummings SR (*see* Alloggiamento et al). 1999;137:596-600 (Editorial)
Curtis AB (*see* Wood et al). 1999;137:682-5

D

Dagianti A (*see* Sessa et al). 1999;137:1116-9
Dall'Agata A (*see* Nosir et al). 1999;137:134-43
Dall'Agata A, McGhie J, Taaris MA, Cromme-Dijkhuis AH, Spitaels SEC, Breburda CSM, Roelandt JRTC, Bogers AJJC. Secundum atrial septal defect is a dynamic three-dimensional entity. 1999;137:1175-81
Danchin N (*see* Abdelmouttaleb et al). 1999;137:346-51
Danchin N (*see* Vaur et al). 1999;137:49-58
Dassen WR (*see* Ophuis et al). 1999;137:846-53
Dauerman HL (*see* Cohen and Dauerman). 1999;137:193-5 (Editorial)
Davis VG (*see* Kizer et al). 1999;137:79-92
Dean LS (*see* Liu et al). 1999;137:292-7
de Boer M-J (*see* Ottervanger et al). 1999;137:1169-72
de Feyter PJ. Bailout coronary stenting: not always a foolproof safety net. 1999;137:579-81 (Editorial)

Degertekin M (*see* Gencbay et al). 1999;137:463-8
Dellborg M (*see* Gardtman et al). 1999;137:821-9
DeLong ER, Simons T. Statistical issues in cost-effectiveness analysis. 1999;137:S47-S50
del Piano M (*see* Sessa et al). 1999;137:1116-9
Del Rosso A, Bartoletti A. Nitrate-stimulated tilt test. 1999;137:575-6 (Letter reply)
Demirel S (*see* Özcan et al). 1999;137:375-6 (Letter)
Dendale P (*see* Aerts and Dendale). 1999;137:575 (Letter)
Denes P (*see* Rios et al). 1999;137:1057-61
Deseñzani P (see Giustina et al). 1999;137:1035-43
Destro A (see Ottani et al). 1999;137:284-91
de Swart H (see Ophuis et al). 1999;137:846-53
Detrano RC (see Doherty et al). 1999;137:806-15
Detsky AS. Terminology I would like to see disappear. 1999;137:S51-S52
de Zwaan C (see Ophuis et al). 1999;137:846-53
Díaz R (see Bazzino et al). 1999;137:322-31
Dindar I (see Gencbay et al). 1999;137:463-8
Ding W (see Li et al). 1999;137:1145-52
Di Pietro M (see Sessa et al). 1999;137:1116-9
Dittrich HC, Pearce LA, Asinger RW, McBride R, Webel R, Zabalgoitia M, Pennock GD, Safford RE, Rothbart RM, Halperin JL, Hart RS. Left atrial diameter in nonvalvular atrial fibrillation: an echocardiographic study. 1999;137:494-9
Doba N (see Tomiyama et al). 1999;137:543-8
Dodge JR (see Gibson et al). 1999;137:1179-1184
Dodge JT Jr (see Gibson et al). 1999;137:169-79
Doherty M (see Mayet et al). 1999;137:678-81
Doherty TM, Detrano RC, Mautner SL, Mautner GC, Shavelle RM. Coronary calcium: the good, the bad, and the uncertain. 1999;137:806-15
Donohue TJ (see Kern et al). 1999;137:1129-36
Donovan CL (see Hughes et al). 1999;137:1163-8
Donovan J (see Kostamaa et al). 1999;137:482-8
Dorian P (see Shapiro et al). 1999;137:1100-6
Douglas PS. Diastolic dysfunction: old dog, new tricks. 1999;137:777-8 (Editorial)
Du C-C (see Lin et al). 1999;137:658-65
Du X (see Li et al). 1999;137:1145-52
Dubroca I (see Vaur et al). 1999;137:49-58
Dyduszynski A (see Sadowski et al). 1999;137:792-8

E

Egstrup K (*see* Emanuelsson et al). 1999;137:854-62
Egstrup K (*see* Poulsen et al). 1999;137:910-8
Eisenberg MJ (*see* Fagih and Eisenberg). 1999;137:1173-8
Eisenberg P (*see* Becker et al). 1999;137:59-71
Ellenbogen KA, Wood MA, Stambler BS. Intravenous therapy for atrial fibrillation: more choices, more questions, more trials. 1999;137:992-5
Ellenbogen KA (*see* Wood et al). 1999;137:682-5
Ellis SC (*see* Thel et al). 1999;137:264-73
Ellis SG (*see* Hasdai et al). 1999;137:612-20
Ellström J (*see* Emanuelsson et al). 1999;137:854-62
Emanuelsson H, Egstrup K, Nikus K, Ellström J, Glud T, Pater C, Scheibel M, Tisell A, Tötterman K-J, Forsby M. Antianginal efficacy of the combination of felodipine-metoprolol 10/100 mg compared with each drug alone in patients with stable effort-induced angina pectoris: a multicenter parallel group study. 1999;137:854-62
Engelen D (*see* Ophuis et al). 1999;137:846-53
Erel J (*see* Kang et al). 1999;137:949-57
Espinola N (*see* Salazar et al). 1999;137:714-20
Espínola-Zavaleta N, Vargas-Barrón J, Colmenares-Galvis T, Cruz-Cruz F, Romero-Cárdenas A, Keirns C, Amigo M-C. Echocardiographic evaluation of patients with primary antiphospholipid syndrome. 1999;137:974-9
Etienne S (*see* Vaur et al). 1999;137:49-58
Evans JC (*see* Lauer et al). 1999;137:903-9
Every NR, Ritchie JL. Variations in the use of cardiac procedures: what is the explanation? 1999;137:588-9 (Editorial)

F

Fagih B, Eisenberg MJ. Reuse of angioplasty catheters and risk of Creutzfeldt-Jakob disease. 1999;137:1173-8
Fahrenbruch CE (*see* Peckova et al). 1999;137:512-15
Falahati A, Sharkey SW, Christensen D, McCoy M, Miller EA, Murakami MA, Apple FS. Implementation of serum cardiac troponin I as the marker for detection of acute myocardial infarction. 1999;137:332-7
Fallen EL, Coates G, Nahmias C, Chirakal R, Beanlands R, Wahl L, Woodcock G, Thomson M, Kamath M. Recovery rates of regional sympathetic reinnervation and myocardial blood flow after acute myocardial infarction. 1999;137:863-9
Farb A, Lindsay J Jr, Virmani R. Pathology of bailout coronary stenting in human beings. 1999;137:621-31
Farvid AR (*see* Hiro et al). 1999;137:476-81
Fein SA (*see* Torossov et al). 1999;137:154-61
Feldman LJ (*see* Benamer et al). 1999;137:815-20
Ferrières J (*see* Vaur et al). 1999;137:49-58
Ferrini D (*see* Ottani et al). 1999;137:284-91
Feuerstein IM (*see* O'Malley et al). 1999;137:932-41
Finkelhor RS, Youssefi ME, Lamont WE, Bahler RC. Embolic risk based on aortic atherosclerotic morphologic features and aortic spontaneous echocardiographic contrast. 1999;137:1088-93
Fischer A, Özbek C, Bay W, Hamann GE. Cerebral microemboli during left heart catheterization. 1999;137:162-8
Fitzpatrick L (*see* Kostamaa et al). 1999;137:482-8
Flaker GC, McGowan DJ, Boechler M, Fortune G, Gage B. Underutilization of antithrombotic therapy in elderly rural patients with atrial fibrillation. 1999;137:307-12
Fleishman CE (*see* Ota et al). 1999;137:958-67
Foale RA (*see* Mayet et al). 1999;137:678-81
Forsby M (*see* Emanuelsson et al). 1999;137:854-62
Fortune G (*see* Flaker et al). 1999;137:307-12
Fox NL (*see* Van de Werf et al). 1999;137:786-91
Franzosi MG (*see* Villella et al). 1999;137:443-52
Frasure-Smith N (*see* Shapiro et al). 1999;137:1100-6
French PA, Ohman EM. The abbreviated life of acronyms. 1999;137:577-8 (Editorial)
Frick M (*see* Samad et al). 1999;137:489-93
Friedman JD (*see* Kang et al). 1999;137:949-57
Frishman WH, Cheng A. Secondary prevention of myocardial infarction: role of β-adrenergic blockers and angiotensin-converting enzyme inhibitors. 1999;137:S25-S34
Fujioka M (*see* Munt et al). 1999;137:298-306

G

Gage B (*see* Flaker et al). 1999;137:307-12
Gagnon JP. What constitutes a useful health economic study for the pharmaceutical industry? 1999;137:S62-S66
Galatius S, Wroblewski H, Sorensen VB, Bie P, Parving H-H, Kastrup J. Endothelin and von Willebrand factor as parameters of endothelial function in idiopathic dilated cardiomyopathy: different stimuli for release before and after heart transplantation. 1999;137:549-54
Galton DJ (*see* Winkelmann et al). 1999;137:698-705
Galvani M (*see* Ottani et al). 1999;137:284-91
Garcia T (*see* Johnson et al). 1999;137:1137-44
Gardtman M, Dellborg M, Brunnhage C, Lindkvist J, Waagstein L, Herlitz J. Effect of intravenous metoprolol before hospital admission on chest pain in suspected acute myocardial infarction. 1999;137:821-9

Garratt KN. Nothin' but 'net? 1999;137:187-9 (Editorial)
Garratt KN (*see* Hasdai et al). 1999;137:612-20
Gaultier CJ (*see* Benamer et al). 1999;137:815-20
Gaziano JM (*see* Strauss et al). 1999;137:458-62
Gen H (*see* Izumi et al). 1999;137:419-26
Gencbay M, Degertekin M, Basaran Y, Yaymaci B, Izgi A, Dindar I, Turan F. Microbubbles associated with mechanical heart valves: their relation with serum lactic dehydrogenase levels. 1999;137:463-8
Genès N (*see* Vaur et al). 1999;137:49-58
Gersh BJ, Solomon A. Lone atrial fibrillation: epidemiology and natural history. 1999;137:592-5 (Editorial)
Gerson MC (*see* Lenihan et al). 1999;137:942-8
Gheorghiade M (*see* Borzak et al). 1999;137:358-45
Gheorghiade M (*see* Johnson and Gheorghiade). 1999;137:989-81 (Editorial)
Gibbons RV (*see* O'Malley et al). 1999;137:932-41
Gibler WB. Understanding true risk: evaluating troponins in the emergency setting. 1999;137:985-6 (Editorial)
Gibson CM, Ryan K, Sparano A, Moynihan JL, Rizzo M, Kelley M, Marble SJ, Laham R, Simons M, McClusky T, Dodge JT Jr. Angiographic methods to assess human coronary angiogenesis. 1999;137:169-79
Gibson CM, Ryan KA, Kelley M, Rizzo MJ, Mesley R, Murphy S, Swanson J, Marble SJ, Dodge JT, Giugliano RP, Cannon CP, Antman EM. Methodologic drift in the assessment of TIMI grade 3 flow and its implications with respect to the reporting of angiographic trial results. 1999;137:1179-1184
Giles WH (*see* Haldeman et al). 1999;137:352-60
Gimple LW (*see* Ragosta et al). 1999;137:250-7
Giordano A (*see* Giustina et al). 1999;137:1035-43
Giugliano RP (*see* Gibson et al). 1999;137:1179-1184
Giustina A, Volterrani M, Manelli F, Desenzani P, Poiesi C, Lorusso R, Giordano A. Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure. 1999;137:1035-43
Glassman AH (*see* Shapiro et al). 1999;137:1100-6
Glick HA (see Boyko et al). 1999;137:S115-S119
Glower DD. Does pregnancy affect the durability of valvular bioprostheses? 1999;137:590-1 (Editorial)
Glud T (see Emanuelsson et al). 1999;137:854-62
Godfrey E (see Hochman et al). 1999;137:313-21
Gold MR (see Peters et al). 1999;137:100-3
Goldberg RJ, Gurwitz JH. Disseminating the results of clinical trials to community-based practitioners: is anyone listening? 1999;137:4-7 (Editorial)
Goldberg RJ (see Mukamal et al). 1999;137:1120-8
Goldman L (see Johnson et al). 1999;137:1137-44
Goldstein D (see Scardi et al). 1999;137:686-91
Gonzales E (see Lehmann et al). 1999;137:274-83
Graff O (see Norgaard et al). 1999;137:1062-1069
Grande P (see Holmvang et al). 1999;137:24-33
Graney MJ (see Mirvis and Graney). 1999;137:706-13
Granger CB (see Alexander et al). 1999;137:799-805
Granger CB (see Hasdai et al). 1999;137:612-20
Granger CB (see Kleiman et al). 1999;137:12-23
Granger CB (see Sadowski et al). 1999;137:792-8
Grayburn PA (see Main and Grayburn). 1999;137:144-53
Grayzel J (see Kern et al). 1999;137:1129-36
Griffin BP (see Leung et al). 1999;137:427-34
Groß W (see Winkelmann et al). 1999;137:698-705
Grossman P (see Watkins and Grossman). 1999;137:453-7
Grumbach K (see Alexander et al). 1999;137:919-27
Guéant J-L (see Abdelmouttaleb et al). 1999;137:346-51
Gurwitz JH (see Goldberg and Gurwitz). 1999;137:4-7 (Editorial)

H

Haarmann W (*see* Zeymer et al). 1999;137: 34-8
Haase KK, Mahrholdt H, Schröder S, Baumbach A, Oberhoff M, Herdeg C, Karsch KR. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty. 1999;137:234-40
Hahn EA (*see* Olshansky et al). 1999;137:878-86
Haldeman GA, Croft JB, Giles WH, Rashidee A. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. 1999;137:352-60
Hallstrom AP (*see* Peckova et al). 1999;137:512-15
Halperin JL (*see* Dittrich et al). 1999;137:494-9
Hamann GE (*see* Fischer et al). 1999;137:162-8
Handler CE (*see* Mayet et al). 1999;137:678-81
Harbison G (*see* Rowland et al). 1999;137:126-33
Harrington RA, Califf RM, Holmes DR Jr, Pieper KS, Lincoff AM, Berdan LG, Thompson TD, Topol EJ. Is all unstable angina the same? Insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). 1999;137:227-33
Harrison W (*see* Shapiro et al). 1999;137:1100-6
Hart RG (*see* Dittrich et al). 1999;137:494-9
Hartz VL (*see* Olshansky et al). 1999;137:878-86
Hasdai D, Lerman A, Rihal CS, Criger DA, Garratt KN, Betriu A, White HD, Topol EJ, Granger CB, Ellis SG, Califf RM, Holmes DR Jr. Smoking status and outcome after primary coronary angioplasty for acute myocardial infarction. 1999;137:612-20
Hausmann D (*see* Blessing et al). 1999;137:368-71
Havstad S (*see* Borzak et al). 1999;137:338-45
Hearne MJ (*see* Malenka et al). 1999;137:632-8
Hearne MJ (*see* Wennberg et al). 1999;137:639-45
Hebert J (*see* Becker et al). 1999;137:59-71
Held AC (*see* Becker et al). 1999;137:59-71
Hendel R (*see* Becker et al). 1999;137:59-71
Henneke KH, Regar E, König A, Werner F, Klauss V, Metz J, Theisen K, Mudra H. Impact of target lesion calcification on coronary stent expansion after rotational atherectomy. 1999;137:93-9
Hennekens CH. Update on aspirin in the treatment and prevention of cardiovascular disease. 1999;137:S9-S13
Herdeg C (*see* Haase et al). 1999;137:234-40
Herlitz J (*see* Gardtman et al). 1999;137:821-9
Hettleman B (*see* Malenka et al). 1999;137:632-8
Himburt D (*see* Benamer et al). 1999;137:815-20
Himura Y (*see* Izumi et al). 1999;137:419-26
Hirasaki S, Nakamura T, Kuribayashi T, Shima T, Matsubara K, Azuma A, Sugihara H, Kohno Y, Nakagawa M. Abnormal course, abnormal flow, and systolic compression of the septal perforator associated with impaired myocardial perfusion in hypertrophic cardiomyopathy. 1999;137:109-17
Hiraumi Y (*see* Ohuchi et al). 1999;137:1185-1194
Hiro T, Leung CY, Karimi H, Farvid AR, Tobis JM. Angle dependence of intravascular ultrasound imaging and its feasibility in tissue characterization of human atherosclerotic tissue. 1999;137:476-81
Hirsch R (*see* Shapira et al). 1999;137:721-5
Hirschson Prado A (*see* Bazzino et al). 1999;137:322-31
Hishitani T (*see* Hoshino et al). 1999;137:535-42
Hlatky MA. Role of economic models in randomized clinical trials. 1999;137:S41-S46
Hlatky MA (*see* Hornberger et al). 1999;137:1153-1162
Hochman JS, Sleeper LA, Godfrey E, McKinlay SM, Sanborn T, Col J, LeJemtel T. Should we emergently revascularize occluded coronaries for cardiogenic shock: an international randomized trial of emergency PTCA/CABG—trial design. 1999;137:313-21
Höjer J (*see* Samad et al). 1999;137:489-93
Holmes DR Jr (*see* Harrington et al). 1999;137:227-33
Holmes DR Jr (*see* Hasdai et al). 1999;137:612-20
Holmvang L, Clemmensen P, Wagner G, Grande P. Admission standard electrocardiogram for early risk stratification in patients with unstable coronary artery disease not eligible for acute revascularization therapy: a TRIM substudy. 1999;137:24-33
Hoorntje JCA (*see* Ottervanger et al). 1999;137:1169-72

Hornberger J, Bloch DA, Hlatky MA, Baumgartner W. Patient preferences in coronary revascularization. 1999;137:1153-1162
Hoshino K, Ogawa K, Hishitani T, Kitazawa R, Uehara R. Hypoplastic left heart syndrome: duration of survival without surgical intervention. 1999;137:535-42
Houbracken K (*see* Van de Werf et al). 1999;137:786-91
Housholder SD (*see* Borzak et al). 1999;137:338-45
Hughes GC, Landolfo KP, Lowe JE, Coleman RB, Donovan CL. Diagnosis, incidence, and clinical significance of early postoperative ischemia after transmyocardial laser revascularization. 1999;137:1163-8
Humar F (*see* Scardi et al). 1999;137:686-91
Humphries J (*see* Ragosta et al). 1999;137:250-7
Hurley T (*see* Becker et al). 1999;137:59-71

I

Ianelli G (*see* Losi et al). 1999;137:968-73
Iga K (*see* Izumi et al). 1999;137:419-26
Ilardo C (*see* Abdelmouttaleb et al). 1999;137:346-51
Imai Y (*see* Tomiyama et al). 1999;137:543-8
Imbar S (*see* Mazur et al). 1999;137:104-8
Insa L (*see* Bodí et al). 1999;137:1107-15
Ishii M (*see* Kosuge et al). 1999;137:522-7
Ishihara T (*see* Yotsukura et al). 1999;137:672-7
Ishikawa K (*see* Yotsukura et al). 1999;137:672-7
Ishikawa T (*see* Kosuge et al). 1999;137:522-7
Ishikawa Y, Bach JR, Minami R. Cardioprotection for Duchenne's muscular dystrophy. 1999;137:895-902
Istvan JA, Lee WW, Buist AS, Connett JE. Relation of salivary cotinine to blood pressure in middle-aged cigarette smokers. 1999;137:928-31
Iyer SS (*see* Liu et al). 1999;137:292-7
Izgi A (*see* Gencbay et al). 1999;137:463-8
Izumi C, Iga K, Himura Y, Gen H, Konishi T. Influence of gravity on pulmonary venous flow velocity patterns: analysis of left and right pulmonary venous flow velocities in left and right decubitus positions. 1999;137:419-26

J

Jackson JD. Economics and cost-effectiveness in evaluating the value of cardiovascular therapy: lipid-lowering therapies—an industry perspective. 1999;137:S105-S110
Jaffe AS (*see* Ottani et al). 1999;137:284-91
Jansen W (*see* Ophuis et al). 1999;137:846-53
Jensen G (*see* Vaage-Nilsen et al). 1999;137:1070-4
Jensen SE (*see* Poulsen et al). 1999;137:910-8
Jesse R (*see* Becker et al). 1999;137:59-71
Jesse RL. Myocardial necrosis in "pure unstable angina": identification of high-risk subgroups or a contradiction in terms? 1999;137:190-2 (Editorial)
Jhandyala R (see Tobis et al). 1999;137:241-9
Jiang JW (see Shapiro et al). 1999;137:1100-6
Johansen JB (see Nørgaard et al). 1999;137:1062-1069
Johnson M (see Chen et al). 1999;137:516-21
Johnson MR, Gheorghiade M. Growth hormone therapy in patients with congestive heart failure: need for further research. 1999;137:989-81 (Editorial)
Johnson PA, Goldman L, Sacks DB, Garcia T, Albano M, Bezai M, Pedan A, Cook EF, Lee TH. Cardiac troponin T as a marker for myocardial ischemia in patients seen at the emergency department for active chest pain. 1999;137:1137-44
Jones DL (see O'Malley et al). 1999;137:932-41
Jortner R (see Shapira et al). 1999;137:721-5
Joseph C (see Borzak et al). 1999;137:338-45
Juliard J-M (see Benamer et al). 1999;137:815-20

K

Kahler J (*see* Lewandowski and Kahler). 1999;137:S94-S96
Kajiwara T (*see* Yotsukura et al). 1999;137:672-7
Kalaria VG. Predictability of left ventricular thrombus by mitral regurgitation. 1999;137:374-5 (Letter reply)
Kamath M (*see* Fallen et al). 1999;137:863-9
Kamiya T (*see* Ohuchi et al). 1999;137:1185-1194
Kanagaratnam P (*see* Mayet et al). 1999;137:678-81
Kang X, Berman DS, Lewin H, Miranda R, Erel J, Friedman JD, Amanullah AM. Comparative ability of myocardial perfusion single-photon emission computed tomography to detect coronary artery disease in patients with and without diabetes mellitus. 1999;137:949-57
Kapadia S (*see* Ballal et al). 1999;137:469-75
Karimi H (*see* Hiro et al). 1999;137:476-81
Karsch KR (*see* Haase et al). 1999;137:234-40
Karve M (*see* Ragosta et al). 1999;137:250-7
Kasaoka S (*see* Kostamaa et al). 1999;137:482-8
Kasaoka S (*see* Tobis et al). 1999;137:241-9
Kasprzak JD (*see* Nosir et al). 1999;137:134-43
Kastrup J (*see* Galatius et al). 1999;137:549-54
Kawaguchi A, Miyatake K, Yutani C, Beppu S, Tsushima M, Yamamura T, Yamamoto A. Characteristic cardiovascular manifestation in homozygous and heterozygous familial hypercholesterolemia. 1999;137:410-18
Keeley EC, Weaver WD. Infarct size: thrombolysis versus PTCA. 1999;137:1007-9 (Editorial)
Keijns C (*see* Espínola-Zavaleta et al). 1999;137:974-9
Kellett MA Jr (*see* Malenka et al). 1999;137:632-8
Kellett MA Jr (*see* Wennberg et al). 1999;137:639-45
Kelley M (*see* Gibson et al). 1999;137:169-79
Kelley M (*see* Gibson et al). 1999;137:1179-1184
Kern MJ, Aguirre FV, Caracciolo EA, Bach RG, Donohue TJ, Lasorda D, Ohman EM, Schnitzler RN, King DL, Ohley WJ, Grayzel J. Hemodynamic effects of new intra-aortic balloon counterpulsation timing methods in patients: a multicenter evaluation. 1999;137:1129-36
Kessler JM. Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspective. 1999;137:S111-S114
Kim C, Kwok YS, Saha S, Redberg RF. Diagnosis of suspected coronary artery disease in women: a cost-effectiveness analysis. 1999;137:1019-27
Kimmelstiel CD. (*see* Kuvin and Kimmelstiel). 1999;137:216-26
Kimura K (*see* Kosuge et al). 1999;137:522-7
King DL (*see* Kern et al). 1999;137:1129-36
Kinsey C (*see* Senior et al). 1999;137:646-52
Kisslo J (*see* Ota et al). 1999;137:958-67
Kitazawa R (*see* Hoshino et al). 1999;137:535-42
Kizer JR, Cannon CP, McCabe CH, Mueller HS, Schweiger MJ, Davis VG, Perritt R, Antman EM. Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. 1999;137:79-92
Klapdor R (*see* Nägele et al). 1999;137:1044-9
Klaus V(*see* Henneke et al). 1999;137:93-9
Kleiman NS. Much ado about thrombin. 1999;137:196-8 (Editorial)
Kleiman NS, Granger CB, White HD, Armstrong P, Ardissino D, Van de Werf F, Zoldeyhi P, Thompson TD, Califf RM, Topol EJ. Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb. 1999;137:12-23
Klein AL (*see* Thamilarasan and Klein). 1999;137:381-3 (Editorial)
Klein B (*see* Winkelmann et al). 1999;137:698-705
Klein GJ (*see* Krahn et al). 1999;137:870-7
Klein LW (*see* Calvin and Klein). 1999;137:199-202 (Editorial)
Kloner RA, Leor J. Natural disaster plus wake-up time: a deadly combination of triggers. 1999;137:779-81 (Editorial)
Kohno Y (*see* Hirasaki et al). 1999;137:109-17

Kong DF (*see* Alexander and Kong). 1999;137:180-6
Kong DF (*see* Alexander and Kong). 1999;137:555-74
Kong DF (*see* Sadowski et al). 1999;137:792-8
König A (*see* Henneke et al). 1999;137:93-9
Konishi T (*see* Izumi et al). 1999;137:419-26
Konstam MA. Mining gold standards from ivory towers: quality of care in academic medical centers. 1999;137:987-8 (Editorial)
Kostamaa H, Donovan J, Kasaoka S, Tobis J, Fitzpatrick L. Calcified plaque cross-sectional area in human arteries: correlation between intravascular ultrasound and undecalcified histology. 1999;137:482-8
Kosuge M, Kimura K, Ishikawa T, Kuji N, Tochikubo O, Sugiyama M, Ishii M. Value of ST-segment elevation pattern in predicting infarct size and left ventricular function at discharge in patients with reperfused acute anterior myocardial infarction. 1999;137:522-7
Kraft CD (*see* Munt et al). 1999;137:298-306
Krahn AD, Klein GJ, Yee R, Manda V. The high cost of syncope: cost implications of a new insertable loop recorder in the investigation of recurrent syncope. 1999;137:870-7
Krijne R (*see* Ophuis et al). 1999;137:846-53
Krumholz HM. Thrombolytic therapy: economic considerations. 1999;137:S87-S89
Krumholz HM (*see* Nohria et al). 1999;137:1028-34
Kuch J (*see* Sadowski et al). 1999;137:792-8
Kudat H (*see* Özcan et al). 1999;137:375-6 (Letter)
Kuji N (*see* Kosuge et al). 1999;137:522-7
Kulbertus HE *see* Piérard et al). 1999;137:500-11
Kuribayashi T (*see* Hirasaki et al). 1999;137:109-17
Kusniec J (*see* Mazur et al). 1999;137:104-8
Kuvin JT, Kimmelstiel CD. Infectious causes of atherosclerosis. 1999;137:216-26
Kuwahara A (*see* Ohuchi et al). 1999;137:1185-94
Kwok YS (*see* Kim et al). 1999;137:1019-27

L

Labovitz AJ. Transesophageal echocardiography and unexplained cerebral ischemia: a multicenter follow-up study. 1999;137:1082-7
Ladenson JH (*see* Ottani et al). 1999;137:284-91
Ladwig KH, Röll G, Breithardt G, Borggrefe M. Extracardiac contributions to chest pain perception in patients 6 months after acute myocardial infarction. 1999;137:528-34
Laham R (*see* Gibson et al). 1999;137:169-79
Lahiri A (*see* Senior et al). 1999;137:646-52
Lai C-W (*see* Lin et al). 1999;137:658-65
Lamont WE (*see* Finkelhor et al). 1999;137:1088-93
Lancellotti P (*see* Piérard et al). 1999;137:500-11
Landolfo KP (*see* Hughes et al). 1999;137:1163-8
Lapsley D (*see* Strauss et al). 1999;137:458-62
Larson MG (*see* Lauer et al). 1999;137:903-9
Lasorda D (*see* Kern et al). 1999;137:1129-36
Lauer MS, Larson MG, Evans JC, Levy D. Association of left ventricular dilatation and hypertrophy with chronotropic incompetence in the Framingham Heart Study. 1999;137:903-9
Lee WW (*see* Istvan et al). 1999;137:928-31
Lee TH. What constitutes a useful economic study? The health systems perspective. 1999;137:S67-S70
Lee TH (*see* Johnson et al). 1999;137:1137-44
Legget ME (*see* Munt et al). 1999;137:298-306
Lehmann KG, Gonzales E, Tri BD, Vaziri ND. Systemic and translesional activation of coagulation, fibrinolytic, and inhibitory systems in candidates for coronary angioplasty: basal state and effect of successful dilation. 1999;137:274-83
LeJemtel T (*see* Hochman et al). 1999;137:313-21
Lenihan DJ, Rosenbaum AF, Burwinkel P, Tseng C-Y, Bhat G, Wagoner L, Walsh RA, Gerson MC. Prediction of human transplantation arteriopathy and coronary events with lung/heart count ratios during intravenous dipyridamole thallium-201 imaging. 1999;137:942-8
Leor J (*see* Kloner and Leor). 1999;137:779-81 (Editorial)
Lequin MH (*see* Nosir et al). 1999;137:134-43
Lerman A (*see* Hasdai et al). 1999;137:612-20
Lespérance F (*see* Shapiro et al). 1999;137:1100-6
Leung CY (see Hiro et al). 1999;137:476-81
Leung DY, Armstrong G, Griffin BP, Thomas JD, Marwick TH. Latent left ventricular dysfunction in patients with mitral regurgitation: feasibility of measuring diminished contractile reserve from a simplified model of noninvasively derived left ventricular pressure-volume loops. 1999;137:427-34
Levy D (see Lauer et al). 1999;137:903-9
Lewandowski CA, Kahler J. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies: a health system perspective on thrombolytic therapy for acute myocardial infarction. 1999;137:S94-S96
Lewin H (see Kang et al). 1999;137:949-57
Li D, Zhao L, Liu M, Du X, Ding W, Zhang J, Mehta JL. Kinetics of tumor necrosis factor a in plasma and the cardioprotective effect of a monoclonal antibody to tumor necrosis factor a in acute myocardial infarction. 1999;137:1145-52
Li KI (*see* Tan and Li). 1999;137:770-3 (Editorial)
Liao Y, McGee DL, Cooper RS, Sutkowski MBE. How generalizable are coronary risk prediction models? Comparison of Framingham and two national cohorts. 1999;137:837-45
Liem A (*see* Ottervanger et al). 1999;137:1169-72
Lien W-P (*see* Lin et al). 1999;137:658-65
Lin I-N (*see* Lin et al). 1999;137:658-65
Lin J-L, Chan H-L, Du C-C, Lin I-N, Lai C-W, Lin K-T, Wu C-P, Tseng Y-Z, Lien W-P. Long-term
β-blocker therapy improves autonomic nervous regulation in advanced congestive heart failure: a longitudinal heart rate variability study. 1999;137:658-65
Lin K-T (*see* Lin et al). 1999;137:658-65
Lincoff AM (*see* Harrington et al). 1999;137:227-33
Lincoff AM (*see* Thel et al). 1999;137:264-73
Lindkvist J (*see* Gardtman et al). 1999;137:821-9
Lindsay J Jr (*see* Farb et al). 1999;137:621-31
Liu M (*see* Li et al). 1999;137:1145-52
Liu MW, Luo JF, Dean LS, Baxley WA, Iyer SS, Sutor RJ, Negus B, Roubin GS. Long-term follow-up study of coronary reconstruction with multiple stents. 1999;137:292-7
Llàcer A (*see* Bodí et al). 1999;137:1107-15
Longu G (*see* Mercuro et al). 1999;137:692-7
López-Merino V (*see* Bodí et al). 1999;137:1107-15
Losi MA, Betocchi S, Briguori C, Manganelli F, Ciampi Q, Pace L, Iannelli G, Spampinato N, Chiariello M. Determinants of aortic artifacts during transesophageal echocardiography of the ascending aorta. 1999;137:968-73
Lorusso R (*see* Giustina et al). 1999;137:1035-43
Loubinoux J (*see* Abdelmouttaleb et al). 1999;137:346-51
Lowe JE (*see* Hughes et al). 1999;137:1163-8
Lozniewski A (*see* Abdelmouttaleb et al). 1999;137:346-51
Lucas FL (*see* Wennberg et al). 1999;137:639-45
Luce BR (*see* Stewart et al). 1999;137:S53-S61
Luo JF (*see* Liu et al). 1999;137:292-7
Luyten A (*see* Van de Werf et al). 1999;137:786-91

M

Maclure M (*see* Mukamal et al). 1999;137:1120-8
Madsen B (*see* Norgaard et al). 1999;137:1062-9
Maggioni AP (*see* Villella et al). 1999;137:443-52
Mahrholdt H (*see* Haase et al). 1999;137:234-40
Maier V (*see* Winkelmann et al). 1999;137:698-705
Main ML, Grayburn PA. Clinical applications of transpulmonary contrast echocardiography. 1999;137:144-53

Malenka DJ, O'Rourke D, Miller MA, Hearne MJ, Shubrooks S, Kellett MA Jr, Robb JF, O'Meara JR, VerLee P, Bradley WA, Wennberg D, Ryan T Jr, Vaitkus PT, Hettleman B, Watkins MW, McGrath PD, O'Connor GT. Cause of in-hospital death in 12,232 consecutive patients undergoing percutaneous transluminal coronary angioplasty. 1999;137:632-8
Malenka DJ (*see* Wennberg et al). 1999;137:639-45
Manda V (*see* Krahn et al). 1999;137:870-7
Manelli F (*see* Giustina et al). 1999;137:1035-43
Manganelli F (*see* Losi et al). 1999;137:968-73
Mansukhani P (*see* Tobis et al). 1999;137:241-9
Marble SJ (*see* Gibson et al). 1999;137:169-79
Marble SJ (*see* Gibson et al). 1999;137:1179-84
Mark DB, Simons TA. Fundamentals of economic analysis. 1999;137:S38-S40
Mark DB, Simons TA. Use of abciximab: comparative economic data. 1999;137:S123-S125
Mark DB (*see* Califf et al). 1999;137:S90-S93
Mark DB (*see* Califf and Mark). 1999;137:769 (Editorial)
Marshall PR. Coronary stents: an industry perspective. 1999;137:S138-S141
Marwick TH. ST-segment elevation after myocardial infarction: what does it mean and when is it useful? 1999;137:1002-4 (Editorial)
Marwick TH (*see* Ballal et al). 1999;137:469-75
Marwick TH (*see* Leung et al). 1999;137:427-34
März W (*see* Winkelmann et al). 1999;137:698-705
Mason JW (*see* Olshansky et al). 1999;137:878-86
Massie BM (*see* Alexander et al). 1999;137:919-27
Matheis G (*see* Winkelmann et al). 1999;137:698-705
Matsubara K (*see* Hirasaki et al). 1999;137:109-17
Mautner GC (*see* Doherty et al). 1999;137:806-15
Mautner SL (*see* Doherty et al). 1999;137:806-15
Mayet J, Kanagaratnam P, Shahi M, Senior R, Doherty M, Poulter NR, Sever PS, Handler CE, McG Thom SA, Foale RA. QT dispersion in athletic left ventricular hypertrophy. 1999;137:678-81
Maynard C. Understanding racial differences in the use of thrombolytic therapy: what more do we need to know? 1999;137:211-12 (Editorial)
Mazur A, Strasberg B, Kusniec J, Imbar S, Sulkes J, Abramson E, Sclarovsky S. Relation between QT dispersion and slow intraventricular conduction in patients with acute anterior wall myocardial infarction. 1999;137:104-8
Mazzone C (*see* Scardi et al). 1999;137:686-91
McBride R (*see* Dittrich et al). 1999;137:494-9
McCabe CH (*see* Kizer et al). 1999;137:79-92
McCabe CH (*see* Van de Werf et al). 1999;137:786-91
McClusky T (*see* Gibson et al). 1999;137:169-79
McCoy M (*see* Falahati et al). 1999;137:332-7
McCullough PM (*see* Sharma and McCullough). 1999;137:373-4 (Letter)
McGee DL (*see* Liao et al). 1999;137:837-45
McGhie J (*see* Dall'Agata et al). 1999;137:1175-81
McGowan DJ (*see* Flaker et al). 1999;137:307-12
McGrath PD (*see* Malenka et al). 1999;137:632-8
McG Thom SA (*see* Mayet et al). 1999;137:678-81
McKinlay SM (*see* Hochman et al). 1999;137:313-21
Mehta JL (*see* Li et al). 1999;137:1145-52
Mehta RH, Bates ER. Coronary stent implantation in acute myocardial infarction. 1999;137:603-11
Mele E (*see* Bazzino et al). 1999;137:322-31
Mercuro G, Longu G, Zoncu S, Cherchi A. Impaired forearm blood flow and vasodilator reserve in healthy postmenopausal women. 1999;137:692-7
Mesley R (*see* Gibson et al). 1999;137:1179-84
Metz J (*see* Henneke et al). 1999;137:93-9
Miller DD. Lung thallium imaging in coronary transplant arteriopathy: "Ce n'est pas un pipe." 1999;137:782-5 (Editorial)
Miller EA (*see* Falahati et al). 1999;137:332-7
Miller MA (*see* Malenka et al). 1999;137:632-8
Minami R (*see* Ishikawa et al). 1999;137:895-902
Miranda R (*see* Kang et al). 1999;137:949-57
Mirvis DM, Graney MJ. Variations in the use of cardiac procedures in the Veterans Health Administration. 1999;137:706-13
Mitamura H (*see* Yoshikawa et al). 1999;137:666-71
Mittleman MA (*see* Mukamal et al). 1999;137:1120-8
Mitrovic V (*see* Schulz et al). 1999;137:887-94
Miyake-Hull CY (*see* Munt et al). 1999;137:298-306
Miyatake K (*see* Kawaguchi et al). 1999;137:410-18
Mizelle KM, Rice MJ, Sahn DJ. Practical application of 3-dimensional echocardiography in evaluation of atrial septal defects. 1999;137:1000-1
Moliterno DJ (*see* Patel and Moliterno). 1999;137:8-11 (Editorial)
Morris LA. Product labeling and pharmacoeconomic information. 1999;137:S78-80
Morton DJ (*see* Nohria et al). 1999;137:1028-1034
Moynihan JL (*see* Gibson et al). 1999;137:169-79
Mroczek WJ V (*see* Neutel et al). 1999;137:118-25
Mudra H (*see* Henneke et al). 1999;137:93-9
Mueller HS (*see* Kizer et al). 1999;137:79-92
Mügge A (*see* Blessing et al). 1999;137:368-71
Mukamal KJ, Mittleman MA, Maclure M, Sherwood JB, Goldberg RJ, Muller JE. Recent aspirin use is associated with smaller myocardial infarct size and lower likelihood of Q-wave infarction. 1999;137:1120-8
Muller JE. Circadian variation and triggering of acute coronary events. 1999;137:S1-S8
Muller JE (see Mukamal et al). 1999;137:1120-8
Munt B, Legget ME, Kraft CD, Miyake-Hull CY, Fujioka M, Otto CM. Physical examination in valvular aortic stenosis: correlation with stenosis severity and prediction of clinical outcome. 1999;137:298-306
Murakami MA (see Falahati et al). 1999;137:332-7
Murayama A (see Yoshikawa et al). 1999;137:666-71
Murphy S (see Gibson et al). 1999;137:1179-84

N

Nägele H, Bahlo M, Klapdor R, Schaeperkoetter D, Rödiger W. CA 125 and its relation to cardiac function. 1999;137:1044-9
Nahmias C (*see* Fallen et al). 1999;137:863-9
Nakagawa M (*see* Hirasaki et al). 1999;137:109-17
Nakamura T (*see* Hirasaki et al). 1999;137:109-17
Nakayama T (*see* Tomiyama et al). 1999;137:543-8
Nartowicz E (*see* Sadowski et al). 1999;137:792-8
Nash IS. Improving outcomes of percutaneous coronary intervention. 1999;137:979-982 (Editorial)
Nauck M (*see* Winkelmann et al). 1999;137:698-705
Naylor CD (*see* Cohen et al). 1999;137:1012-8
Negishi K (*see* Yoshikawa et al). 1999;137:666-71
Negus B (*see* Liu et al). 1999;137:292-7
Nešković AN, Otasevic P, Bojic M, Popovic AD. Association of Killip class on admission and left ventricular dilatation after myocardial infarction: a closer look into an old clinical classification. 1999;137:361-7
Neugebauer A (*see* Rother et al). 1999;137:766-7 (Letter)
Neuhaus K-L (*see* Zeymer et al). 1999;137: 34-8
Neutel JM, Buckalew V, Chrysant SG, Mroczek WJ, Ruff DA, Weber M. Efficacy and tolerability of tasosartan, a novel angiotensin II receptor blocker: results from a 10-week, double-blind, placebo-controlled, dose-titration study. 1999;137:118-25
Nikus K (*see* Emanuelsson et al). 1999;137:854-62
Nishimura T (*see* Yotsukura et al). 1999;137:672-7
Nohria A, Chen Y-T, Morton DJ, Walsh R, Vlasses PH, Krumholz HM. Quality of care for patients hospitalized with heart failure at academic medical centers. 1999;137:1028-1034
Nørgaard BL, Wachtell K, Christensen PD, Madsen B, Johansen JB, Christiansen EH, Graff O, Simonsen EH. Efficacy and safety of intravenously administered dofetilide in acute termination of

atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. 1999;137:1062-9
Nosir YFM, Stoker J, Kasprzak JD, Lequin MH, Dall'Agata A, Ten Cate FJ, Roelandt JRTC. Paraplane analysis from precordial three-dimensional echocardiographic data sets for rapid and accurate quantification of left ventricular volume and function: a comparison with magnetic resonance imaging. 1999;137:134-43

O

Oberhoff M (*see* Haase et al). 1999;137:234-40
O'Connor CM (*see* Mark and O'Connor). 1999;137:39-48
O'Connor CM (*see* Shapiro et al). 1999;137:1100-6
O'Connor GT (*see* Malenka et al). 1999;137:632-8
O'Connor GT (*see* Wennberg et al). 1999;137:639-45
Ogawa K (*see* Hoshino et al). 1999;137:535-42
Ogawa S (*see* Yoshikawa et al). 1999;137:666-71
Oh P (*see* Cohen et al). 1999;137:1012-8
Ohazama CJ (*see* Ota et al). 1999;137:958-67
Ohley WJ (*see* Kern et al). 1999;137:1129-36
Ohman EM (*see* French and Ohman). 1999;137:577-8 (Editorial)
Ohman EM (*see* Kern et al). 1999;137:1129-36
Ohuchi H, Hiraumi Y, Tasato H, Kuwahara A, Chado H, Toyohara K, Arakaki Y, Yagihara T, Kamiya T. Comparison of the right and left ventricle as a systemic ventricle during exercise in patients with congenital heart disease. 1999;137:1185-94
Olshansky B, Hahn EA, Hartz VL, Prater SP, Mason JW. Clinical significance of syncope in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial. 1999;137:878-86
Olsovsky M (*see* Peters et al). 1999;137:100-3
O'Malley PG, Taylor AJ, Gibbons RV, Feuerstein IM, Jones DL, Vernalis M, Brazaitis M. Rationale and design of the Prospective Army Calcium (PACC) Study: utility of electron beam computed tomography as a screening test for coronary artery disease and as an intervention for risk factor modification among young, asymptomatic, active-duty United States Army personnel. 1999;137:932-41
O'Meara JR (*see* Malenka et al). 1999;137:632-8
Ophuis TJMO, Bär FW, Vermeer F, Krijne R, Jansen W, de Swart H, van Ommen V, de Zwaan C, Engelen D, Dassen WR, Wellens HJJ. Early referral for intentional rescue PTCA after initiation of thrombolytic therapy in patients admitted to a community hospital because of a large acute myocardial infarction. 1999;137:846-53
O'Rourke D (*see* Malenka et al). 1999;137:632-8
O'Rourke D (*see* Wennberg et al). 1999;137:639-45
Osterhues HH. Time-dependent changes of HRV after PTCA. 1999;137:376 (Letter reply)
Ota T, Fleishman CE, Strub M, Stetten G, Ohazama CJ, von Ramm OT, Kisslo J. Real-time, three-dimensional echocardiography: feasibility of dynamic right ventricular volume measurement with saline contrast. 1999;137:958-67
Otasevic PA (*see* Nešković et al). 1999;137:361-7
Ottani F, Galvani M, Ferrini D, Ladenson JH, Puggioni R, Destro A, Baccos D, Bosi S, Ronchi A, Rusticali F, Jaffe AS. Direct comparison of early elevations of cardiac troponin T and I in patients with clinical unstable angina. 1999;137:284-91
Ottervanger JP, Liem A, de Boer M-J, van't Hof AWJ, Suryapranata H, Hoorntje JCA, Zijlstra F. Limitation of myocardial infarct size after primary angioplasty: is a higher patency the only mechanism? 1999;137:1169-72
Otto CM (*see* Munt et al). 1999;137:298-306
Oz MC. What kind of coronary revascularization does the average American really want? 1999;137:1005-6
Özbek C (*see* Fischer et al). 1999;137:162-8
Özcan M, Kudat H, Akkaya V, Sözen AB, Demirel S, Tükek T. Time-dependent changes of HRV after PTCA. 1999;137:375-6 (Letter)

P

Pace L (*see* Losi et al). 1999;137:968-73
Pandullo C (*see* Scardi et al). 1999;137:686-91
Paolasso E (*see* Bazzino et al). 1999;137:322-31
Parving H-H (*see* Galatius et al). 1999;137:549-54
Patel VB, Moliterno DJ. Bedside activated partial thromboplastin time monitoring: just a matter of time? 1999;137:8-11 (Editorial)
Pater C (*see* Emanuelsson et al). 1999;137:854-62
Paviotti C (*see* Bazzino et al). 1999;137:322-31
Pearce LA (*see* Dittrich et al). 1999;137:494-9
Peckova M, Fahrenbruch CE, Cobb LA, Hallstrom AP. Weekly and seasonal variation in the incidence of cardiac arrests. 1999;137:512-15
Pedan A (*see* Johnson et al). 1999;137:1137-44
Pelini M (*see* Peters et al). 1999;137:100-3
Penco M (*see* Sessa et al). 1999;137:1116-9
Pennock GD (*see* Dittrich et al). 1999;137:494-9
Perritt R (*see* Kizer et al). 1999;137:79-92
Peters RW, Shorofsky SR, Pelini M, Olsovsky M, Gold MR. Overdrive atrial pacing for conversion of atrial flutter: comparison of postoperative with nonpostoperative patients. 1999;137:100-3
Peterson ED, Batchelor WB. Percutaneous intervention in the very elderly: weighing the risks and benefits. 1999;137:585-7 (Editorial)
Pfeiffer D (*see* Rother et al). 1999;137:766-7 (Letter)
Pieper KS (*see* Harrington et al). 1999;137:227-33
Piepoli M, Ponikowski P, Clark AL, Banasiak W, Capucci A, Coats AJS. A neural link to explain the "muscle hypothesis" of exercise intolerance in chronic heart failure. 1999;137:1050-6
Piérard LA, Lancellotti P, Kulbertus HE. ST-segment elevation during dobutamine stress testing predicts functional recovery after acute myocardial infarction. 1999;137:500-11
Pinski SL, Sgarbossa EB, Ching E, Trohman RG. A comparison of 50-J versus 100-J shocks for direct-current cardioversion of atrial flutter. 1999;137:439-42
Piombo A (*see* Bazzino et al). 1999;137:322-31
Poiesi C (*see* Giustina et al). 1999;137:1035-43
Poletti A (*see* Scardi et al). 1999;137:686-91
Ponikowski P (*see* Piepoli et al). 1999;137:1050-6
Popovic AD (*see* Nešković et al). 1999;137:361-7
Portaluppi F (*see* Smolensky and Portaluppi). 1999;137:S14-S24
Potts J (*see* Rowland et al). 1999;137:126-33
Potts T (*see* Rowland et al). 1999;137:126-33
Poulsen SH, Jensen SE, Egstrup K. Longitudinal changes and prognostic implications of left ventricular diastolic function in first acute myocardial infarction. 1999;137:910-8
Poulter NR (*see* Mayet et al). 1999;137:678-81
Powers ER (*see* Ragosta et al). 1999;137:250-7
Prater SP (*see* Olshansky et al). 1999;137:878-86
Prystowsky EN (*see* Anderson and Prystowsky). 1999;137:388-409 (Prog. cardiol.)
Puggioni R (*see* Ottani et al). 1999;137:284-91

Q

Quinton H (*see* Wennberg et al). 1999;137:639-45

R

Ragosta M, Karve M, Brezynski D, Humphries J, Sanders JM, Sarembock IJ, Gimple LW, Powers ER. Effectiveness of heparin in preventing thrombin generation and thrombin activity in patients undergoing coronary intervention. 1999;137:250-7
Rashidee A (*see* Haldeman et al). 1999;137:352-60
Rasmussen V (*see* Vaage-Nilsen et al). 1999;137:1070-4
Raza M (see Chen et al). 1999;137:516-21
Redberg RF (see Alloggiamento et al). 1999;137:596-600 (Editorial)

Redberg RF (see Kim et al). 1999;137:1019-27
Regar E (see Henneke et al). 1999;137:93-9
Reiffel JA. Predictability of response rates, efficacy, risks, and intolerance with sotalol when used for sustained ventricular arrhythmias. 1999;137:372-3 (Letter)
Remy L (see Alexander et al). 1999;137:919-27
Rice MJ (see Mizelle et al). 1999;137:1000-1
Rihal CS (see Hasdai et al). 1999;137:612-20
Rios AS, Silber EN, Bavishi N, Varga P, Burton BK, Clark WA, Denes P. Effect of long-term beta-blockade on aortic root compliance in patients with Marfan syndrome. 1999;137:1057-61
Ritchie JL (*see* Every and Ritchie). 1999;137:588-9 (Editorial)
Rizzo M (*see* Gibson et al). 1999;137:169-79
Rizzo MJ (*see* Gibson et al). 1999;137:1179-84
Robb JF (*see* Malenka et al). 1999;137:632-8
Robb JF (*see* Wennberg et al). 1999;137:639-45
Rödiger W (*see* Nägele et al). 1999;137:1044-9
Roelandt JRTC (*see* Nosir et al). 1999;137:134-43
Roelandt JRTC (*see* Dall'Agata et al). 1999;137:1175-81
Röll G (*see* Ladwig et al). 1999;137:528-34
Román L (*see* Salazar et al). 1999;137:714-20
Romero-Cárdenas A (*see* Espínola-Zavaleta et al). 1999;137:974-9
Ronchi A (*see* Ottani et al). 1999;137:284-91
Rosenbaum AF (*see* Lenihan et al). 1999;137:942-8
Rosner F (*see* Chen et al). 1999;137:516-21
Rothbart RM (*see* Dittrich et al). 1999;137:494-9
Rother T, Neugebauer A, Pfeiffer D. Significance of coronary flow reserve. 1999;137:766-7 (Letter)
Roubin GS (*see* Liu et al). 1999;137:292-7
Rowell R (*see* Alexander et al). 1999;137:919-27
Rowland T, Potts J, Potts T, Son-Hing J, Harbison G, Sandor G. Cardiovascular responses to exercise in children and adolescents with myocardial dysfunction. 1999;137:126-33
Rubin D (*see* Ballal et al). 1999;137:469-75
Ruff DA V (*see* Neutel et al). 1999;137:118-25
Rumberger JA. Coronary artery calcifications: "...empty your cup..." 1999;137:774-6 (Editorial)
Russ AP (*see* Winkelmann et al). 1999;137:698-705
Rusticali F (*see* Ottani et al). 1999;137:284-91
Ryan K (*see* Gibson et al). 1999;137:169-79
Ryan KA (*see* Gibson et al). 1999;137:1179-84
Ryan T Jr (*see* Malenka et al). 1999;137:632-8

S

Sabaté M (*see* Bruining et al). 1999;137:207-10 (Editorial)
Sacks DB (*see* Johnson et al). 1999;137:1137-44
Sadowski Z (*see* Alexander et al). 1999;137:799-805
Sadowski ZP, Alexander JH, Skrabucha B, Dyduszynski A, Kuch J, Nartowicz E, Swiatecka G, Kong DF, Granger CB. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. 1999;137:792-8
Safford RE (*see* Dittrich et al). 1999;137:494-9
Sagie A (*see* Shapira et al). 1999;137:721-5
Saha S (*see* Kim et al). 1999;137:1019-27
Sahn DJ (*see* Mizelle et al). 1999;137:1000-1
Sakata K, Shirotani M, Yoshida H, Urano T, Takada Y, Takada A. Differential effects of enalapril and nitrendipine on the fibrinolytic system in essential hypertension. 1999;137:1094-1099
Sakata K (*see* Yotsukura et al). 1999;137:672-7
Sakuma Y (*see* Tomiyama et al). 1999;137:543-8
Salazar E, Espinola N, Román L, Casanova JM. Effect of pregnancy on the duration of bovine pericardial bioprostheses. 1999;137:714-20
Samad BA, Frick M, Höjer J, Urstad MJ. Early low-dose dobutamine echocardiography predicts late functional recovery after thrombolyzed acute myocardial infarction. 1999;137:489-93
Sanborn T (*see* Hochman et al). 1999;137:313-21
Sanchis J (*see* Bodí et al). 1999;137:1107-15
Sanders JM (*see* Ragosta et al). 1999;137:250-7
Sanderson JE, Yu CM, Young RP, Shum IOL, Wei S, Arumanayagam M, Woo KS. Influence of gene polymorphisms of the renin-angiotensin system on clinical outcome in heart failure among the Chinese. 1999;137:653-7
Sandor G (*see* Rowland et al). 1999;137:126-33
Santino I (*see* Sessa et al). 1999;137:1116-9
Sarelin H (*see* Van de Werf et al). 1999;137:786-91
Sarembock IJ (*see* Ragosta et al). 1999;137:250-7
Sarfati I (*see* Benamer et al). 1999;137:815-20
Scardi S, Mazzone C, Pandullo C, Goldstein D, Poletti A, Humar F. Lone atrial fibrillation: prognostic differences between paroxysmal and chronic forms after 10 years of follow-up. 1999;137:686-91
Schaeffer S (*see* Senior et al). 1999;137:646-52
Schaeperkoetter D (*see* Nägele et al). 1999;137:1044-9
Scheibel M (*see* Emanuelsson et al). 1999;137:854-62
Schmier JK (*see* Stewart et al). 1999;137:S53-S61
Schnitzler RN (*see* Kern et al). 1999;137:1129-36
Schönburg M (*see* Schulz et al). 1999;137:887-94
Schröder S (*see* Haase et al). 1999;137:234-40
Schrogie JJ. Health system perspective regarding glycoprotein IIb/IIIa inhibitor therapy. 1999;137:S126-S128
Schulman DS. Significance of coronary flow reserve. 1999;137:768 (Letter reply)
Schulman KA (*see* Boyko et al). 1999;137:S115-S119
Schulz O, Mitrovic V, Schönburg M, Thormann J. High-dose enoximone to evaluate reversibility of pulmonary hypertension: is there a diagnostic value of neurohormonal measurements? 1999;137:887-94
Schwartz JS. Comparative economic data regarding lipid-lowering drugs. 1999;137:S97-S104
Schweiger MJ (*see* Kizer et al). 1999;137:79-92
Sclarovsky (*see* Mazur et al). 1999;137:104-8
Secknus M-A (*see* Ballal et al). 1999;137:469-75
Sengupta A (*see* Wennberg et al). 1999;137:639-45
Senior R, Basu S, Kinsey C, Schaeffer S, Lahiri A. Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction. 1999;137:646-52
Senior R (*see* Mayet et al). 1999;137:678-81
Serruys PW (*see* Bruining et al). 1999;137:207-10 (Editorial)
Sessa R, Di Pietro M, Santino I, del Piano M, Varveri A, Dagnati A, Penco M. *Chlamydia pneumoniae* infection and atherosclerotic coronary disease. 1999;137:1116-9
Sever PS (*see* Mayet et al). 1999;137:678-81
Sgarbossa EB (*see* Pinski et al). 1999;137:439-42
Shahi M (*see* Mayet et al). 1999;137:678-81
Shapira Y, Sagie A, Jortner R, Adler Y, Hirsch R. Thrombosis of bileaflet tricuspid valve prosthesis: clinical spectrum and the role of nonsurgical treatment. 1999;137:721-5
Shapiro PA, Lespérance F, Frasure-Smith N, O'Connor CM, Baker B, Jiang JW, Dorian P, Harrison W, Glassman AH. An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial). 1999;137:1100-6
Sharkey SW (*see* Falahati et al). 1999;137:332-7
Sharma ND, McCullough PM. Predictability of left ventricular thrombi by mitral regurgitation. 1999;137:373-4 (Letter)
Shavelle RM (*see* Doherty et al). 1999;137:806-15
Sheffield D (*see* Sheps et al). 1999;137:386-7 (Editorial)
Sheingold SH. The value of cost-effectiveness analysis for reimbursement decisions: perspectives from Medicare. 1999;137:S81-S86
Sheps DS, Sheffield D, Carney RM. Does depression predict more symptoms or more disease? 1999;137:386-7 (Editorial)
Sherwood JB (*see* Mukamal et al). 1999;137:1120-8
Shima T (*see* Hirasaki et al). 1999;137:109-17
Shiojima K (*see* Tomiyama et al). 1999;137:543-8
Shirotani M (*see* Sakata et al). 1999;137:1094-1099
Shorofsky SR (*see* Peters et al). 1999;137:100-3
Shubrooks S (*see* Malenka et al). 1999;137:632-8
Shubrooks SJ Jr (*see* Wennberg et al). 1999;137:639-45
Shum IOL (*see* Sanderson et al). 1999;137:653-7

Siegbahn A (*see* Toss et al). 1999;137:72-8
Sigmon KN (see Thel et al). 1999;137:264-73
Silber EN (see Rios et al). 1999;137:1057-61
Simons M (see Gibson et al). 1999;137:169-79
Simons T (see DeLong and Simons). 1999;137:S47-S50
Simons TA (see Mark and Simons). 1999;137:S123-S125
Simons TS (see Mark and Simons). 1999;137:S38-S40
Simonsen EH (see Norgaard et al). 1999;137:1062-9
Singh A (see Torossov et al). 1999;137:154-61
Skrabucha B (see Sadowski et al). 1999;137:792-8
Slaughter PM (see Cohen et al). 1999;137:1012-8
Sleeper LA (see Hochman et al). 1999;137:313-21
Smith ST (see Borzak et al). 1999;137:338-45
Smolensky MH, Portaluppi F. Chronopharmacology and chronotherapy of cardiovascular medications: relevance to prevention and treatment of coronary heart disease. 1999;137:S14-S24
Solomon A (see Gersh and Solomon). 1999;137:592-5 (Editorial)
Son R (see Tobis et al). 1999;137:241-9
Son-Hing J (see Rowland et al). 1999;137:126-33
Sørensen VB (see Galatius et al). 1999;137:549-54
Sorrentino RA. Is an adenosine challenge a useful test for diagnosing sick sinus syndrome? 1999;137:377-80 (Editorial)
Sorum C (see Vaage-Nilsen et al). 1999;137:1070-4
Sözen AB (see Özcan et al). 1999;137:375-6 (Letter)
Spampinato N (see Losi et al). 1999;137:968-73
Sparano A (see Gibson et al). 1999;137:169-79
Spencer F (see Becker et al). 1999;137:59-71
Spitaels SEC (see Dall'Agata et al). 1999;137:1175-81
Stambler BS (see Ellenbogen et al). 1999;137:992-5
Steg PG (see Benamer et al). 1999;137:815-20
Stetten G (see Ota et al). 1999;137:958-67
Stewart A, Schmier JK, Luce BR. A survey of standards and guidelines for cost-effectiveness analysis in health care. 1999;137:S53-S61
Stoker J (see Nosir et al). 1999;137:134-43
Strasberg B (see Mazur et al). 1999;137:104-8
Strauss WE, Lapsley D, Gaziano JM. Comparative efficacy and tolerability of low-dose pravastatin versus lovastatin in patients with hypercholesterolemia. 1999;137:458-62
Strub M (see Ota et al). 1999;137:958-67
Stump D (see Califf et al). 1999;137:S90-S93
Sturm M (see Blessing et al). 1999;137:368-71
Sugihara H (see Hirasaki et al). 1999;137:109-17
Sugiyama M (see Kosuge et al). 1999;137:522-7
Sulkes J (see Mazur et al). 1999;137:104-8
Suryapranata H (see Ottervanger et al). 1999;137:1169-72
Sutkowski MBE (see Liao et al). 1999;137:837-45
Sutor RJ (see Liu et al). 1999;137:292-7
Suzuki M (see Yoshikawa et al). 1999;137:666-71
Swanson J (see Gibson et al). 1999;137:1179-84
Swiatecka G (see Sadowski et al). 1999;137:792-8

T

Taaris MA (*see* Dall'Agata et al). 1999;137:1175-81
Tajer C (*see* Bazzino et al). 1999;137:322-31
Takada A (*see* Sakata et al). 1999;137:1094-1099
Takada Y (*see* Sakata et al). 1999;137:1094-1099
Takahashi T (*see* Yoshikawa et al). 1999;137:666-71
Takle-Newhouse TA (*see* Wood et al). 1999;137:682-5
Tan HL, Lie KI. Prophylactic lidocaine use in acute myocardial infarction revisited in the thrombolytic era. 1999;137:770-3 (Editorial)
Tanasijevic MJ, Antman EM. Diagnostic performance of cardiac troponin I in suspected acute myocardial infarction: implications for clinicians. 1999;137:203-6 (Editorial)
Tasato H (*see* Ohuchi et al). 1999;137:1185-94
Taylor AJ (*see* O'Malley et al). 1999;137:932-41
Tcheng JE (*see* Thel et al). 1999;137:264-73
Tebbe U (*see* Zeymer et al). 1999;137: 34-8
Temple R. Role of government agencies regarding cost-effectiveness claims: FDA perspective. 1999;137:S75-S77
Ten Cate FJ (*see* Nosir et al). 1999;137:134-43
Thamilarasan M, Klein AL. Factors relating to left atrial enlargement in atrial fibrillation: "chicken or the egg" hypothesis. 1999;137:381-3 (Editorial)
Theisen K (*see* Henneke et al). 1999;137:93-9
Thel MC, Califf RM, Tcheng JE, Sigmon KN, Lincoff MA, Topol EJ, Ellis SC. Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. 1999;137:264-73
Thel MC, O'Connor CM. Cardiopulmonary resuscitation: historical perspective to recent investigations. 1999;137:39-48
Thomas JD (*see* Leung et al). 1999;137:427-34
Thompson M (*see* Tobis et al). 1999;137:241-9
Thompson TD (*see* Alexander et al). 1999;137:799-805
Thompson TD (*see* Harrington et al). 1999;137:227-33
Thompson TD (*see* Kleiman et al). 1999;137:12-23
Thomson M (*see* Fallen et al). 1999;137:863-9
Thormann J (*see* Schulz et al). 1999;137:887-94
Tilley B (*see* Borzak et al). 1999;137:338-45
Tisell A (*see* Emanuelsson et al). 1999;137:854-62
Tobis J, Aharonian V, Mansukhani P, Kasaoka S, Jhandyala R, Son R, Browning R, Youngblood L, Thompson M. Video networking of cardiac catheterization laboratories. 1999;137:241-9
Tobis J (*see* Kostamaa et al). 1999;137:482-8
Tobis JM (*see* Hiro et al). 1999;137:476-81
Tochikubo O (*see* Kosuge et al). 1999;137:522-7
Tomiyama H, Nakayama T, Watanabe G, Shiojima K, Sakuma Y, Yamamoto A, Imai Y, Yoshida H, Doba N. Effects of short-acting and long-acting loop diuretics on heart rate variability in patients with chronic compensated congestive heart failure. 1999;137:543-8
Topol EJ (*see* Alexander et al). 1999;137:799-805
Topol EJ (*see* Califf et al). 1999;137:S90-S93
Topol EJ (*see* Harrington et al). 1999;137:227-33
Topol EJ (*see* Hasdai et al). 1999;137:612-20
Topol EJ (*see* Kleiman et al). 1999;137:12-23
Topol EJ (*see* Thel et al). 1999;137:264-73
Torossov M, Singh A, Fein SA. Clinical presentation, diagnosis, and hospital outcome of patients with documented aortic dissection: the Albany Medical Center experience, 1986 to 1996. 1999;137:154-61
Toss H, Wallentin L, Siegbahn A. Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease. 1999;137:72-8
Tötterman K-J (*see* Emanuelsson et al). 1999;137:854-62
Toyohara K (*see* Ohuchi et al). 1999;137:1185-94
Tri BD (*see* Lehmann et al). 1999;137:274-83
Trivi M (*see* Bazzino et al). 1999;137:322-31
Trohman RG (*see* Pinski et al). 1999;137:439-42
Tseng C-Y (*see* Lenihan et al). 1999;137:942-8
Tseng Y-Z (*see* Lin et al). 1999;137:658-65
Tsushima M (*see* Kawaguchi et al). 1999;137:410-18
Tükek T (*see* Özcan et al). 1999;137:375-6 (Letter)
Turan F (*see* Gencbay et al). 1999;137:463-8
Tzivoni D, Butnaru A. Diagnostic accuracy of ST changes detected by exercise testing and ambulatory electrocardiographic monitoring in apparently healthy individuals. 1999;137:996-9 (Editorial)

U

Uehara R (*see* Hoshino et al). 1999;137:535-42
Urano T (*see* Sakata et al). 1999;137:1094-1099
Urstad MJ (*see* Samad et al). 1999;137:489-93

V

Vaage-Nilsen M, Rasmussen V, Sorum C, Jensen G. ST-segment deviation during 24-hour ambulatory electrocardiographic monitor-

ing and exercise stress test in healthy male subjects 51 to 75 years of age: the Copenhagen City Heart Study. 1999;137:1070-4
Vacek JL (see Burnett et al). 1999;137:435-8
Vaitkus PT. Economic impact on physicians and hospitals of proposed changes in Medicare reimbursement for coronary interventions. 1999;137:258-63
Vaitkus PT (see Malenka et al). 1999;137:632-8
Vaitkus PT (see Wennberg et al). 1999;137:639-45
van Ommen V (see Ophuis et al). 1999;137:846-53
van't Hof AWJ (see Ottervanger et al). 1999;137:1169-72
Vargas-Barrón J (see Espínola-Zavaleta et al). 1999;137:974-9
Vaur L, Danchin N, Genès N, Dubroca I, Etienne S, Ferrières J, Cambou J-P. Epidemiology of myocardial infarction in France: therapeutic and prognostic implications of heart failure during the acute phase. 1999;137:49-58
Van de Werf F, Cannon CP, Luyten A, Houbracken K, McCabe CH, Berioli S, Bluhmki E, Sarelin H, Wang-Clow F, Fox NL, Braunwald E. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. 1999;137:786-91
Van de Werf F (see Kleiman et al). 1999;137:12-23
Varga P (see Rios et al). 1999;137:1057-61
Varveri A (see Sessa et al). 1999;137:1116-9
Vaziri ND (see Lehmann et al). 1999;137:274-83
Ver Lee P (see Malenka et al). 1999;137:632-8
Ver Lee P (see Wennberg et al). 1999;137:639-45
Vermeer F (see Ophuis et al). 1999;137:846-53
Vernalis M (see O'Malley et al). 1999;137:932-41
Vicaut E (see Benamer et al). 1999;137:815-20
Villella A (see Villella et al). 1999;137:443-52
Villella M, Villella A, Barlera S, Franzosi MG, Maggioni AP. Prognostic significance of double product and inadequate double product response to maximal symptom-limited exercise stress testing after myocardial infarction in 6296 patients treated with thrombolytic agents. 1999;137:443-52
Virmani R (see Farb et al). 1999;137:621-31
Vlasses PH (see Chen and Vlasses). 1999;137:S71-S74
Vlasses PH (see Nohria et al). 1999;137:1028-1034
Volterrani M (see Giustina et al). 1999;137:1035-43
von Essen R (see Zeymer et al). 1999;137: 34-8
von Ramm OT (see Ota et al). 1999;137:958-67
Voyce SJ (see Becker et al). 1999;137:59-71

W

Waagstein L (*see* Gardtman et al). 1999;137:821-9
Wachtell K (*see* Norgaard et al). 1999;137:1062-9
Wagner G (*see* Holmvang et al). 1999;137:24-33
Wagoner L (*see* Lenihan et al). 1999;137:942-8
Wahl L (*see* Fallen et al). 1999;137:863-9
Wallentin L (*see* Toss et al). 1999;137:72-8
Walsh R (*see* Nohria et al). 1999;137:1028-1034
Walsh RA (*see* Lenihan et al). 1999;137:942-8
Walters J (*see* Chen et al). 1999;137:516-21
Wang-Clow F (*see* Van de Werf et al). 1999;137:786-91
Watanabe G (*see* Tomiyama et al). 1999;137:543-8
Watkins LL, Grossman P. Association of depressive symptoms with reduced baroreflex cardiac control in coronary artery disease. 1999;137:453-7
Watkins MW (*see* Malenka et al). 1999;137:632-8
Weaver WD (*see* Keeley and Weaver). 1999;137:1007-9 (Editorial)
Webel R (*see* Dittrich et al). 1999;137:494-9
Weber M V (*see* Neutel et al). 1999;137:118-25
Wei S (*see* Sanderson et al). 1999;137:653-7
Weisman HF (*see* Anderson et al). 1999;137:S129-S132
Wellens HJJ (*see* Ophuis et al). 1999;137:846-53
Wenger NK. Diagnostic testing for coronary heart disease in women: new information generates new questions. 1999;137:983-984 (Editorial)
Wennberg D (*see* Malenka et al). 1999;137:632-8
Wennberg DE, Malenka DJ, Sengupta A, Lucas FL, Vaitkus PT, Quinton H, O'Rourke D, Robb JF, Kellett MA Jr, Shubrooks SJ Jr, Bradley WA, Hearnes MJ, Ver Lee P, O'Connor GT. Percutaneous transluminal coronary angioplasty in the elderly: epidemiology, clinical risk factors, and in-hospital outcomes. 1999;137:639-45
Werner F (*see* Henneke et al). 1999;137:93-9
Werns SW, Bates ER. The enduring value of Killip classification. 1999;137:213-15 (Editorial)
White HD (*see* Alexander et al). 1999;137:799-805
White HD (*see* Hasdai et al). 1999;137:612-20
White HD (*see* Kleiman et al). 1999;137:12-23
Wieland H (*see* Winkelmann et al). 1999;137:698-705
Willich SN. Cardiac risk: theme con variations. 1999;137:384-5 (Editorial)
Winkelmann BR, Russ AP, Nauck M, Klein B, Böhm BO, Maier V, Zotz R, Matheis G, Wolf A, Wieland H, Groß W, Galton DJ, März W. Angiotensinogen M235T polymorphism is associated with plasma angiotensinogen and cardiovascular disease. 1999;137:698-705
Wolf A (*see* Winkelmann et al). 1999;137:698-705
Wolpers H-G (*see* Blessing et al). 1999;137:368-71
Woo KS (*see* Sanderson et al). 1999;137:653-7
Wood MA, Curtis AB, Takle-Newhouse TA, Ellenbogen KA. Survival of DDD pacing mode after atrioventricular junction ablation and pacing for refractory atrial fibrillation. 1999;137:682-5
Wood MA (*see* Ellenbogen et al). 1999;137:992-5
Woodcock G (*see* Fallen et al). 1999;137:863-9
Wroblewski H (*see* Galatius et al). 1999;137:549-54
Wu C-P (*see* Lin et al). 1999;137:658-65

Y

Yagihara T (*see* Ohuchi et al). 1999;137:1185-94
Yamamoto A (*see* Kawaguchi et al). 1999;137:410-18
Yamamoto A (*see* Tomiyama et al). 1999;137:543-8
Yamamoto A (*see* Yotsukura et al). 1999;137:672-7
Yamamura T (*see* Kawaguchi et al). 1999;137:410-18
Yaymaci B (*see* Gencbay et al). 1999;137:463-8
Yee R (*see* Krahn et al). 1999;137:870-7
Yoshida H (*see* Sakata et al). 1999;137:1094-1099
Yoshida H (*see* Tomiyama et al). 1999;137:543-8
Yoshikawa T, Baba A, Akaishi M, Mitamura H, Ogawa S, Suzuki M, Negishi K, Takahashi T, Murayama A. Neurohumoral activations in congestive heart failure: correlations with cardiac function, heart rate variability, and baroreceptor sensitivity. 1999;137:666-71
Yotsukura M, Yamamoto A, Kajiwara T, Nishimura T, Sakata K, Ishihara T, Ishikawa K. QT dispersion in patients with Duchenne-type progressive muscular dystrophy. 1999;137:672-7
Young RP (*see* Sanderson et al). 1999;137:653-7
Young W (*see* Cohen et al). 1999;137:1012-8
Youngblood L (*see* Tobis et al). 1999;137:241-9
Youssefi ME (*see* Finkelhor et al). 1999;137:1088-93
Yu CM (*see* Sanderson et al). 1999;137:653-7
Yunsheng M (*see* Becker et al). 1999;137:59-71
Yutani C (*see* Kawaguchi et al). 1999;137:410-18

Z

Zabalgoitia M (*see* Dittrich et al). 1999;137:494-9
Zeymer U, Tebbe U, von Essen R, Haarmann W, Neuhaus K-L. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. 1999;137: 34-8
Zhang J (*see* Li et al). 1999;137:1145-52
Zhao L (*see* Li et al). 1999;137:1145-52
Zijlstra F (*see* Ottervanger et al). 1999;137:1169-72
Zoldeyhi P (*see* Kleiman et al). 1999;137:12-23
Zoncu S (*see* Mercuro et al). 1999;137:692-7
Zotz R (*see* Winkelmann et al). 1999;137:698-705

Subject index*

A

Abciximab
Use of abciximab: comparative economic data (Mark and Simons). 1999;137:S123-S125

Accounting
Economic impact on physicians and hospitals of proposed changes in Medicare reimbursement for coronary interventions (Vaitkus). 1999;137:258-63

Adenosine
Is an adenosine challenge a useful test for diagnosing sick sinus syndrome? (Sorrentino). 1999;137: 377-80 (Editorial)
Use of intravenous adenosine as a noninvasive diagnostic test for sick sinus syndrome (Burnett et al). 1999;137:435-8

Adolescence
Cardiovascular responses to exercise in children and adolescents with myocardial dysfunction (Rowland et al). 1999;137:126-33

Adrenergic beta receptor blockades
Effect of long-term β-blockade on aortic root compliance in patients with Marfan syndrome (Rios et al). 1999;137:1057-61
Long-term β-blocker therapy improves autonomic nervous regulation in advanced congestive heart failure: a longitudinal heart rate variability study (Lin et al). 1999;137:658-65
Secondary prevention of myocardial infarction: role of β-adrenergic blockers and angiotensin-converting enzyme inhibitors (Frishman and Cheng). 1999;137:S25-S34

Aged
Percutaneous intervention in the very elderly: weighing the risks and benefits (Peterson and Batchelor). 1999;137:585-7 (Editorial)
Percutaneous transluminal coronary angioplasty in the elderly: epidemiology, clinical risk factors, and in-hospital outcomes (Wennberg et al). 1999;137:639-45
Underutilization of antithrombotic therapy in elderly rural patients with atrial fibrillation (Flaker et al). 1999;137:307-12

Age factors
Relation of salivary cotinine to blood pressure in middle-aged cigarette smokers (Istvan et al). 1999;137:928-31
ST-segment deviation during 24-hour ambulatory electrocardiographic monitoring and exercise stress test in healthy male subjects 51 to 75 years of age: the Copenhagen City Heart Study (Vaage-Nilsen et al). 1999;137:1070-4

American Heart Association
Highlights from the 71st American Heart Association Scientific Sessions: November 8 to 11, 1998 (Alexander et al). 1999;137:555-74

Angina pectoris
Antianginal efficacy of the combination of felodipine-metoprolol 10/100 mg compared with each drug alone in patients with stable effort-induced angina pectoris: a multicenter parallel group study (Emanuelsson et al). 1999;137:854-62

Angina, unstable
Clinical predictors of in-hospital prognosis in unstable angina: ECLA 3 (Bazzino et al). 1999;137:322-31
Defining risk in unstable angina: current trial design does not tell us who should be treated and with what therapy (Calvin and Klein). 1999;137:199-202 (Editorial)
Direct comparison of early elevations of cardiac troponin T and I in patients with clinical unstable angina (Ottani et al). 1999;137:284-91
Elevated cardiac troponin I predicts a high-risk angiographic anatomy of the culprit lesion in unstable angina (Benamer et al). 1999;137:815-20
Is all unstable angina the same? Insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) (Harrington et al). 1999;137:227-33
Myocardial necrosis in "pure unstable angina": identification of high-risk subgroups or a contradiction in terms? (Jesse). 1999;137:190-2 (Editorial)

Angioplasty, balloon
Bailout coronary stenting: not always a foolproof safety net (de Feyter). 1999;137:579-81 (Editorial)
Pathology of bailout coronary stenting in human beings (Farb et al). 1999;137:621-31
Percutaneous transluminal coronary angioplasty in the elderly: epidemiology, clinical risk factors, and in-hospital outcomes (Wennberg et al). 1999;137:639-45
Smoking status and outcome after primary coronary angioplasty for acute myocardial infarction (Hasdai et al). 1999;137:612-20
Systemic and translesional activation of coagulation, fibrinolytic, and inhibitory systems in candidates for coronary angioplasty: basal state and effect of successful dilation (Lehmann et al). 1999;137:274-83
Trends in clinical and economic outcomes of coronary angioplasty from 1992 to 1995: a population-based analysis (Cohen et al). 1999;137:1012-8

Angioplasty, transluminal percutaneous coronary
Cause of in-hospital death in 12,232 consecutive patients undergoing percutaneous transluminal coronary angioplasty (Malenka et al). 1999;137:632-8
Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial (Thel et al). 1999;137:264-73
Early referral for intentional rescue PTCA after initiation of thrombolytic therapy in patients admitted to a community hospital because of a large acute myocardial infarction (Ophuis et al). 1999;137:846-53
Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty (Haase et al). 1999;137:234-40
Improving outcomes of percutaneous coronary intervention (Nash). 1999;137:979-82 (Editorial)
Infarct size: thrombolysis versus PTCA (Keeley and Weaver). 1999;137:1007-9 (Editorial)
Is all unstable angina the same? Insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) (Harrington et al). 1999;137:227-33
Limitation of myocardial infarct size after primary angioplasty: is a higher patency the only mechanism? (Ottervanger et al). 1999;137:1169-72
Percutaneous intervention in the very elderly: weighing the risks and benefits (Peterson and Batchelor). 1999;137:585-7 (Editorial)
Reuse of angioplasty catheters and risk of Creutzfeldt-Jakob disease (Fagih and Eisenberg). 1999;137:1173-8
Reuse of coronary catheters: old questions, new environment (Barbeau). 1999;137:1010-1 (Editorial)
Time-dependent changes of HRV after PTCA (Özcan et al) (Letter); (Osterhues) (Reply). 1999;137:375-6
Why is mortality rate after percutaneous transluminal coronary angioplasty higher in women? (Brodie). 1999;137:582-4 (Editorial)

Angiotensin-converting enzyme inhibitors
ACE inhibitors in the management of congestive heart failure: comparative economic data (Boyko et al). 1999;137:S115-S119
Angiotensin-converting enzyme inhibitors in the management of congestive heart failure: a pharmaceutical industry perspective (Boccuzzi). 1999;137:S120-S122
Cardioprotection for Duchenne's muscular dystrophy (Ishikawa et al). 1999;137:895-902

*January, pp. 1-186; February, pp. 187-376; March, pp. 377-576; April, part 1, pp. 577-768; part 2, pp. S1-S34; May, part 1, pp. 769-978; part 2, pp. S135-S144; June, pp. 979-1194.

Angiotensin-converting enzyme inhibitors—cont'd

Secondary prevention of myocardial infarction: role of β-adrenergic blockers and angiotensin-converting enzyme inhibitors (Frishman and Cheng). 1999;137:S25-S34

Angiotensinogen

Angiotensinogen M235T polymorphism is associated with plasma angiotensinogen and cardiovascular disease (Winkelmann et al). 1999;137:698-705

Anti-arrhythmic agents

Sotalol: an important new antiarrhythmic (Anderson and Prystowsky). 1999;137:388-409 (Prog. cardiol.)

Antiphospholipid syndrome

Echocardiographic evaluation of patients with primary antiphospholipid syndrome (Espinola-Zavaleta et al). 1999;137:974-9

Aorta

Determinants of aortic artifacts during transesophageal echocardiography of the ascending aorta (Losi et al). 1999;137:968-73

Hemodynamic effects of new intra-aortic balloon counterpulsation timing methods in patients: a multicenter evaluation (Kern et al). 1999;137:1129-36

Aortic valve insufficiency

Characteristic cardiovascular manifestation in homozygous and heterozygous familial hypercholesterolemia (Kawaguchi et al). 1999;137:410-18

Aortic valve stenosis

Do cardiologists and general internists differ in testing and treating patients with aortic stenosis or mitral regurgitation? A preliminary study with editorial perspective (Alloggiamento et al). 1999;137:596-600 (Editorial)

Arrhythmias

Predictability of left ventricular thrombus by mitral regurgitation (Sharma and McCullough) (Letter); (Kalaria) (Reply). 1999;137:373-4

Aspirin

Recent aspirin use is associated with smaller myocardial infarct size and lower likelihood of Q-wave infarction (Mukamal et al). 1999;137:1120-8

Update on aspirin in the treatment and prevention of cardiovascular disease (Hennekens). 1999;137:S9-S14

Atherosclerosis

Angle dependence of intravascular ultrasound imaging and its feasibility in tissue characterization of human atherosclerotic tissue (Hiro et al). 1999;137:476-81

Chlamydia pneumoniae infection and atherosclerotic coronary disease (Sessa et al). 1999;137:1116-9

Coronary artery calcifications: "...empty your cup..." (Rumberger). 1999;137:774-6 (Editorial)

Coronary calcium: the good, the bad, and the uncertain (Doherty et al). 1999;137:806-15

Embolic risk based on aortic atherosclerotic morphologic features and aortic spontaneous echocardiographic contrast (Finkelhor et al). 1999;137:1088-93

Impact of target lesion calcification on coronary stent expansion after rotational atherectomy (Henneke et al). 1999;137:93-9

Infectious causes of atherosclerosis (Kuvin and Kimmelstiel). 1999;137:216-26

Atrial fibrillation

Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial (Nørgaard et al). 1999;137:1062-9

Factors relating to left atrial enlargement in atrial fibrillation: "chicken or the egg" hypothesis (Thamilarasan and Klein). 1999;137:381-3 (Editorial)

Intravenous therapy for atrial fibrillation: more choices, more questions, more trials (Ellenbogen et al). 1999;137:992-5 (Editorial)

Left atrial diameter in nonvalvular atrial fibrillation: an echocardiographic study (Dittrich et al). 1999;137:494-9

Lone atrial fibrillation: epidemiology and natural history (Gersh and Solomon). 1999;137:592-5 (Editorial)

Lone atrial fibrillation: prognostic differences between paroxysmal and chronic forms after 10 years of follow-up (Scardi et al). 1999;137:686-91

Survival of DDD pacing mode after atrioventricular junction ablation and pacing for refractory atrial fibrillation (Wood et al). 1999;137:682-5

Underutilization of antithrombotic therapy in elderly rural patients with atrial fibrillation (Flaker et al). 1999;137:307-12

What to do with acute atrial fibrillation? (Califf). 1999;137:601-2 (Editorial)

Atrial flutter

Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial (Nørgaard et al). 1999;137:1062-9

A comparison of 50-J versus 100-J shocks for direct-current cardioversion of atrial flutter (Pinski et al). 1999;137:439-42

Intravenous therapy for atrial fibrillation: more choices, more questions, more trials (Ellenbogen et al). 1999;137:992-5 (Editorial)

Overdrive atrial pacing for conversion of atrial flutter: comparison of postoperative with nonpostoperative patients (Peters et al). 1999;137:100-3

Atrial septal defects

Practical application of 3-dimensional echocardiography in evaluation of atrial septal defects (Mizelle and Sahn). 1999;137:1000-1

Autonomic nervous system

Association of depressive symptoms with reduced baroreflex cardiac control in coronary artery disease (Watkins and Grossman). 1999;137:453-7

Long-term β-blocker therapy improves autonomic nervous regulation in advanced congestive heart failure: a longitudinal heart rate variability study (Lin et al). 1999;137:658-65

Azosemide

Effects of short-acting and long-acting loop diuretics on heart rate variability in patients with chronic compensated congestive heart failure (Tomiyama et al). 1999;137:543-8

B

Balloon dilatation

Much ado about thrombin (Kleiman). 1999;137:196-8 (Editorial)

Baroreflex sensitivity

Association of depressive symptoms with reduced baroreflex cardiac control in coronary artery disease (Watkins and Grossman). 1999;137:453-7

Bedside monitoring

Bedside activated partial thromboplastin time monitoring: just a matter of time? (Patel and Moliterno). 1999;137:8-11 (Editorial)

Blood flow velocity

Impaired forearm blood flow and vasodilator reserve in healthy postmenopausal women (Mercuro et al). 1999;137:692-7

Blood pressure

Relation of salivary cotinine to blood pressure in middle-aged cigarette smokers (Istvan et al). 1999;137:928-31

C

CA 125

CA 125 and its relation to cardiac function (Nägele et al). 1999;137:1044-9

Calcinosis

Calcified plaque cross-sectional area in human arteries: correlation between intravascular ultrasound and undecalcified histology (Kostamaa et al). 1999;137:482-8

Calcinosis—cont'd

Coronary artery calcifications: "...empty your cup..." (Rumberger). 1999;137:774-6 (Editorial)
Impact of target lesion calcification on coronary stent expansion after rotational atherectomy (Henneke et al). 1999;137:93-9

Cardiac arrest

Weekly and seasonal variation in the incidence of cardiac arrests (Peckova et al). 1999;137:512-15

Cardiogenic shock

Should we emergently revascularize occluded coronaries for cardiogenic shock: an international randomized trial of emergency PTCA/CABG—trial design (Hochman et al). 1999;137:313-21

Cardiomyopathy, dilated

Cardioprotection for Duchenne's muscular dystrophy (Ishikawa et al). 1999;137:895-902
Endothelin and von Willebrand factor as parameters of endothelial function in idiopathic dilated cardiomyopathy: different stimuli for release before and after heart transplantation? (Galatius et al). 1999;137:549-54

Cardiomyopathy, hypertrophic

Abnormal course, abnormal flow, and systolic compression of the septal perforator associated with impaired myocardial perfusion in hypertrophic cardiomyopathy (Hiraski et al). 1999;137:109-17

Cardiopulmonary resuscitation

Cardiopulmonary resuscitation: historical perspective to recent investigations (Thel and O'Connor). 1999;137:39-48

Cerebrovascular disorders

Cerebral microemboli during left heart catheterization (Fischer et al). 1999;137:162-8
Transesophageal echocardiography and unexplained cerebral ischemia: a multicenter follow-up study (Labovitz). 1999;137:1082-1086

Chest pain

Cardiac troponin T as a marker for myocardial ischemia in patients seen at the emergency department for active chest pain (Johnson et al). 1999;137:1137-44

Child

Cardiovascular responses to exercise in children and adolescents with myocardial dysfunction (Rowland et al). 1999; 137:126-33

Chlamydia

Chlamydia pneumoniae infection and atherosclerotic coronary disease (Sessa et al). 1999;137:1116-9
Infectious causes of atherosclerosis (Kuvin and Kimmelstiel). 1999;137:216-26

Clinical trials

The abbreviated life of acronyms (French and Ohman). 1999;137:577-8 (Editorial)
Acronyms of clinical trials in cardiology—1998 (Cheng). 1999;137:726-65
Admission standard electrocardiogram for early risk stratification in patients with unstable coronary artery disease not eligible for acute revascularization therapy: a TRIM substudy (Holmvang et al). 1999;137:24-33
Antianginal efficacy of the combination of felodipine-metoprolol 10/100 mg compared with each drug alone in patients with stable effort-induced angina pectoris: a multicenter parallel group study (Emanuelsson et al). 1999;137:854-62
Cardiopulmonary resuscitation: historical perspective to recent investigations (Thel and O'Connor). 1999;137:39-48
Characteristic cardiovascular manifestation in homozygous and heterozygous familial hypercholesterolemia (Kawaguchi et al). 1999;137:410-18
Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial (Thel et al). 1999;137:264-73
Clinical significance of syncope in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial (Clshansky et al). 1999;137:878-86
Comparative efficacy and tolerability of low-dose pravastatin versus lovastatin in patients with hypercholesterolemia (Strauss et al). 1999;137:458-62
Coronary stent implantation in acute myocardial infarction (Mehta and Bates). 1999;137:603-11
Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb (Kleiman et al). 1999;137:12-23
Defining risk in unstable angina: current trial design does not tell us who should be treated and with what therapy (Calvin and Klein). 1999;137:199-202 (Editorial)
Direct comparison of early elevations of cardiac troponin T and I in patients with clinical unstable angina (Ottani et al). 1999;137:284-91
Disseminating the results of clinical trials to community-based practitioners: is anyone listening? (Goldberg and Gurwitz). 1999;137:4-7 (Editorial)
Effectiveness of heparin in preventing thrombin generation and thrombin activity in patients undergoing coronary intervention (Ragosta et al). 1999;137:250-7
Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial (Norgaard et al). 1999;137:1062-9
Efficacy and tolerability of tasosartan, a novel angiotensin II receptor blocker: results from a 10-week, double-blind, placebo-controlled, dose-titration study (Neutel et al). 1999;137:118-25
Epidemiology of myocardial infarction in France: therapeutic and prognostic implications of heart failure during the acute phase (Vaur et al). 1999;137:49-58
Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty (Haase et al). 1999;137:234-40
The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy (Califf et al). 1999;137:S90-S93
Influence of gravity on pulmonary venous flow velocity patterns: analysis of left and right pulmonary venous flow velocities in left and right decubitus positions (Izumi et al). 1999;137:419-26
Intravenous therapy for atrial fibrillation: more choices, more questions, more trials (Ellenbogen et al). 1999;137:992-5 (Editorial)
Is all unstable angina the same? Insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) (Harrington et al). 1999;137:227-33
Latent left ventricular dysfunction in patients with mitral regurgitation: feasibility of measuring diminished contractile reserve from a simplified model of noninvasively derived left ventricular pressure-volume loops (Leung et al). 1999;137:427-34
Long-term follow-up study of coronary reconstruction with multiple stents (Liu et al). 1999;137:292-7
Methodologic drift in the assessment of TIMI grade 3 flow and its implications with respect to the reporting of angiographic trial results (Gibson et al). 1999;137:1179-84
Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction (Sadowski et al). 1999;137:792-8
An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial) (Shapiro et al). 1999;137:1100-6
Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials (Alexander et al). 1999;137:799-805
A randomized, multicenter trial of weight-adjusted intravenous

Clinical trials—cont'd

heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease (Becker et al). 1999;137:59-71

Role of economic models in randomized clinical trials (Hlatky). 1999;137:S41-S46

Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial (Van de Werf et al). 1999;137:786-91

Should we emergently revascularize occluded coronaries for cardiogenic shock: an international randomized trial of emergency PTCA/CABG—trial design (Hochman et al). 1999;137:313-21

Systemic and translesional activation of coagulation, fibrinolytic, and inhibitory systems in candidates for coronary angioplasty: basal state and effect of successful dilation (Lehmann et al). 1999;137:274-83

Treatment of diffuse coronary lesions: a time for randomized trials (Cohen and Dauerman). 1999;137:193-5 (Editorial)

Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: The MILIS-TIMI experience (Kizer et al). 1999;137:79-92

Use of abciximab: comparative economic data (Mark and Simons). 1999;137:S123-S125

Video networking of cardiac catheterization laboratories (Tobis et al). 1999;137:241-9

Contrast agents

Clinical applications of transpulmonary contrast echocardiography (Main and Grayburn). 1999;137:144-53

Coronary angiography

Angiographic methods to assess human coronary angiogenesis (Gibson et al). 1999;137:169-79

Elevated cardiac troponin I predicts a high-risk angiographic anatomy of the culprit lesion in unstable angina (Benamer et al). 1999;137:815-20

Methodologic drift in the assessment of TIMI grade 3 flow and its implications with respect to the reporting of angiographic trial results (Gibson et al). 1999;137:1179-84

Nothin' but 'net? (Garratt). 1999;137:187-9 (Editorial)

Video networking of cardiac catheterization laboratories (Tobis et al). 1999;137:241-9

Coronary calcium

Coronary calcium: the good, the bad, and the uncertain (Doherty et al). 1999;137:806-15

Rationale and design of the Prospective Army Coronary Calcium (PACC) Study: utility of electron beam computed tomography as a screening test for coronary artery disease and as an intervention for risk factor modification among young, asymptomatic, active-duty United States Army personnel (O'Malley et al). 1999;137:932-41

Coronary disease

Chlamydia pneumoniae infection and atherosclerotic coronary disease (Sessa et al). 1999;137:1116-9

C-reactive protein and coronary artery disease: additional evidence of the implication of an inflammatory process in acute coronary syndromes (Abdelmouttaleb et al). 1999;137:346-51

Diagnostic accuracy of ST changes detected by exercise testing and ambulatory electrocardiographic monitoring in apparently healthy individuals (Tzivoni and Butnaru). 1999;137:996-9 (Editorial)

Coronary disease, complications

Does depression predict more symptoms or more disease? (Sheps et al). 1999;137:386-7 (Editorial)

Extracardiac contributions to chest pain perception in patients 6 months after acute myocardial infarction (Ladwig et al). 1999;137:528-34

Coronary disease, diagnosis

Comparative ability of myocardial perfusion single-photon emission computed tomography to detect coronary artery disease in patients with and without diabetes mellitus (Kang et al). 1999;137:949-57

Diagnosis of suspected coronary artery disease in women: a cost-effectiveness analysis (Kim et al). 1999;137:1019-27

Diagnostic testing for coronary heart disease in women: new information generates new questions (Wenger). 1999;137:983-4 (Editorial)

Rationale and design of the Prospective Army Coronary Calcium (PACC) Study: utility of electron beam computed tomography as a screening test for coronary artery disease and as an intervention for risk factor modification among young, asymptomatic, activeduty United States Army personnel (O'Malley et al). 1999;137:932-41

Coronary disease, mortality

Cardiac risk: theme con variations (Willich). 1999;137:384-5 (Editorial)

Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb (Kleiman et al). 1999;137:12-23

Weekly and seasonal variation in the incidence of cardiac arrests (Peckova et al). 1999;137:512-15

Coronary disease, prevention

Chronopharmacology and chronotherapy of cardiovascular medications: relevance to prevention and treatment of coronary heart disease (Smolensky and Portaluppi). 1999;137:S14-S24

Circadian variation and triggering of acute coronary events (Muller). 1999;137:S1-S8

Secondary prevention of myocardial infarction: role of β-adrenergic blockers and angiotensin-converting enzyme inhibitors (Frishman and Cheng). 1999;137:S25-S34

Update on aspirin in the treatment and prevention of cardiovascular disease (Hennekens). 1999;137:S9-S14

Coronary disease, treatment

Evaluating the economic implications of cardiovascular therapeutics (Califf). 1999;137:S35-S37

Coronary flow reserve

Significance of coronary flow reserve (Rother and Pfeiffer) (Letter); (Schulman) (Reply). 1999;137:766-8

Cost-benefit analysis

Consortium perspective: what constitutes a useful economic study? (Chen and Vlasses). 1999;137:S71-S74

Coronary stents: a health system perspective (Ahmad). 1999;137:S142-S144

Coronary stents: an industry perspective (Marshall). 1999;137:S138-S141

Economics and cost-effectiveness in evaluating the value of cardiovascular therapy: lipid-lowering therapies—an industry perspective (Jackson). 1999;137:S105-S110

Evaluating the economic implications of cardiovascular therapeutics (Califf). 1999;137:S35-S37

Evaluation of the cost-effectiveness of coronary stenting: a societal perspective (Cohen). 1999;137:S133-137

Fundamentals of economic analysis (Mark and Simons). 1999;137:S38-S40

Health system perspective regarding glycoprotein IIb/IIIa inhibitor therapy (Schrogie). 1999;137:S126-S128

The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy (Califf et al). 1999;137:S90-S93

Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspective (Kessler). 1999;137:S111-S114

Role of economic models in randomized clinical trials (Hlatky). 1999;137:S41-S46

Statistical issues in cost-effectiveness analysis (DeLong and Simons). 1999;137:S47-S50

Cost-benefit analysis—cont'd

A survey of standards and guidelines for cost-effectiveness analysis in health care (Stewart et al). 1999;137:S53-S61
Terminology I would like to see disappear (Detsky). 1999;137:S51-S52
The value of cost-effectiveness analyses for reimbursement decisions: perspectives from Medicare (Sheingold). 1999;137:S81-S86
Thrombolytic therapy: economic considerations (Krumholz). 1999;137:S87-S89
Use of abciximab: comparative economic data (Mark and Simons). 1999;137:S123-S125
What constitutes a useful economic study? The health systems perspective (Lee). 1999;137:S67-S70
What constitutes a useful health economic study for the pharmaceutical industry? (Gagnon). 1999;137:S62-S66

Cost control

ACE inhibitors in the management of congestive heart failure: comparative economic data (Boyko et al). 1999;137:S115-S119
Comparative economic data regarding lipid-lowering drugs (Schwartz). 1999;137:S97-S104
Economics and cost-effectiveness in evaluating the value of cardiovascular therapy: lipid-lowering therapies—an industry perspective (Jackson). 1999;137:S105-S110
Role of government agencies regarding cost-effectiveness claims: FDA perspective (Temple). 1999;137:S75-S77

Costs and cost analysis

Consortium perspective: what constitutes a useful economic study? (Chen and Vlasses). 1999;137:S71-S74
Diagnosis of suspected coronary artery disease in women: a cost-effectiveness analysis (Kim et al). 1999;137:1019-27
Fundamentals of economic analysis (Mark and Simons). 1999;137:S38-S40
The high cost of syncope: cost implications of a new insertable loop recorder in the investigation of recurrent syncope (Krahn et al). 1999;137:870-7
An industry perspective on health economics studies (Anderson et al). 1999;137:S129-S132
Statistical issues in cost-effectiveness analysis (DeLong and Simons). 1999;137:S47-S50
A survey of standards and guidelines for cost-effectiveness analysis in health care (Stewart et al). 1999;137:S53-S61

C-reactive protein

C-reactive protein and coronary artery disease: additional evidence of the implication of an inflammatory process in acute coronary syndromes (Abdelmouttaleb et al). 1999;137:346-51

Creutzfeldt-Jakob disease

Reuse of angioplasty catheters and risk of Creutzfeldt-Jakob disease (Fagih and Eisenberg). 1999;137:1173-8
Reuse of coronary catheters: old questions, new environment (Barbeau). 1999;137:1010-1 (Editorial)

Curriculum in cardiology

Infectious causes of atherosclerosis (Kuvin and Kimmelstiel). 1999;137:216-26

Cytomegalovirus

Infectious causes of atherosclerosis (Kuvin and Kimmelstiel). 1999;137:216-26

D

Death

Cause of in-hospital death in 12,232 consecutive patients undergoing percutaneous transluminal coronary angioplasty (Malenka et al). 1999;137:632-8
Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb (Kleiman et al). 1999;137:12-23

Depression

Association of depressive symptoms with reduced baroreflex cardiac control in coronary artery disease (Watkins and Grossman). 1999;137:453-7
Does depression predict more symptoms or more disease? (Sheps et al). 1999;137:386-7 (Editorial)
Extracardiac contributions to chest pain perception in patients 6 months after acute myocardial infarction (Ladwig et al). 1999;137:528-34
An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial) (Shapiro et al). 1999;137:1100-6

Diabetes mellitus

Comparative ability of myocardial perfusion single-photon emission computed tomography to detect coronary artery disease in patients with and without diabetes mellitus (Kang et al). 1999;137:949-57

Diagnostic imaging

Angle dependence of intravascular ultrasound imaging and its feasibility in tissue characterization of human atherosclerotic tissue (Hiro et al). 1999;137:476-81
Calcified plaque cross-sectional area in human arteries: correlation between intravascular ultrasound and undecalcified histology (Kostamaa et al). 1999;137:482-8
Cardiovascular responses to exercise in children and adolescents with myocardial dysfunction (Rowland et al). 1999;137:126-33
Clinical applications of transpulmonary contrast echocardiography (Main and Grayburn). 1999;137:144-53
Clinical presentation, diagnosis, and hospital outcome of patients with documented aortic dissection: the Albany Medical Center experience, 1986 to 1996 (Torossov et al). 1999;137:154-61
Comparative ability of myocardial perfusion single-photon emission computed tomography to detect coronary artery disease in patients with and without diabetes mellitus (Kang et al). 1999;137:949-57
Early low-dose dobutamine echocardiography predicts late functional recovery after thrombolyzed acute myocardial infarction (Samad et al). 1999;137:489-93
Left atrial diameter in nonvalvular atrial fibrillation: an echocardiographic study (Dittrich et al). 1999;137:494-9
Microbubbles associated with mechanical heart valves: their relation with serum lactic dehydrogenase levels (Gencbay et al). 1999;137:463-8
Paraplane analysis from precordial three-dimensional echocardiographic data sets for rapid and accurate quantification of left ventricular volume and function: a comparison with magnetic resonance imaging (Nosir et al). 1999;137:134-43
Prediction of human transplantation arteriopathy and coronary events with lung/heart count ratios during intravenous dipyridamole thallium-201 imaging (Lenihan et al). 1999;137:942-8
Prognosis of patients with vascular disease after clinical evaluation and dobutamine stress echocardiography (Ballal et al). 1999;137:469-75
Rationale and design of the Prospective Army Coronary Calcium (PACC) Study: utility of electron beam computed tomography as a screening test for coronary artery disease and as an intervention for risk factor modification among young, asymptomatic, active-duty United States Army personnel (O'Malley et al). 1999;137:932-41
Real-time, three-dimensional echocardiography: feasibility of dynamic right ventricular volume measurement with saline contrast (Ota et al). 1999;137:958-67
Secundum atrial septal defect is a dynamic three-dimensional entity (Dall'Agata et al). 1999;137:1175-81

Diastole

Diastolic dysfunction: old dog, new tricks (Douglas). 1999;137:777-8 (Editorial)
Longitudinal changes and prognostic implications of left ventricular diastolic function in first acute myocardial infarction (Poulsen et al). 1999;137:910-18

Dissection
Clinical presentation, diagnosis, and hospital outcome of patients with documented aortic dissection: the Albany Medical Center experience, 1986 to 1996 (Torossov et al). 1999;137:154-61
Diuretics
Effects of short-acting and long-acting loop diuretics on heart rate variability in patients with chronic compensated congestive heart failure (Tomiyama et al). 1999;137:543-8
Dobutamine
Early low-dose dobutamine echocardiography predicts late functional recovery after thrombolyzed acute myocardial infarction (Samad et al). 1999;137:489-93
Prognosis of patients with vascular disease after clinical evaluation and dobutamine stress echocardiography (Ballal et al). 1999;137:469-75
ST-segment elevation during dobutamine stress testing predicts functional recovery after acute myocardial infarction (Piérard et al). 1999;137:500-11
Dofetilide
Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial (Nørgaard et al). 1999;137:1062-9
Intravenous therapy for atrial fibrillation: more choices, more questions, more trials (Ellenbogen et al). 1999;137:992-5 (Editorial)
Drug therapy
Chronopharmacology and chronotherapy of cardiovascular medications: relevance to prevention and treatment of coronary heart disease (Smolensky and Portaluppi). 1999;137:S14-S24
Comparative economic data regarding lipid-lowering drugs (Schwartz). 1999;137:S97-S104
Economics and cost-effectiveness in evaluating the value of cardiovascular therapy: lipid-lowering therapies—an industry perspective (Jackson). 1999;137:S105-S110
Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial (Nørgaard et al). 1999;137:1062-9
Efficacy and tolerability of tasosartan, a novel angiotensin II receptor blocker: results from a 10-week, double-blind, placebo-controlled, dose-titration study (Neutel et al). 1999;137:118-25
Intravenous therapy for atrial fibrillation: more choices, more questions, more trials (Ellenbogen et al). 1999;137:992-5 (Editorial)
Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspective (Kessler). 1999;137:S111-S114

E

Echocardiography
Clinical applications of transpulmonary contrast echocardiography (Main and Grayburn). 1999;137:144-53
Early low-dose dobutamine echocardiography predicts late functional recovery after thrombolyzed acute myocardial infarction (Samad et al). 1999;137:489-93
Echocardiographic evaluation of patients with primary antiphospholipid syndrome (Espínola-Zavaleta et al). 1999;137:974-9
Embolic risk based on aortic atherosclerotic morphologic features and aortic spontaneous echocardiographic contrast (Finkelhor et al). 1999;137:1088-93
Factors relating to left atrial enlargement in atrial fibrillation: "chicken or the egg" hypothesis (Thamilarasan and Klein). 1999;137:381-3 (Editorial)
Left atrial diameter in nonvalvular atrial fibrillation: an echocardiographic study (Dittrich et al). 1999;137:494-9
Paraplane analysis from precordial three-dimensional echocardiographic data sets for rapid and accurate quantification of left ventricular volume and function: a comparison with magnetic resonance imaging (Nosir et al). 1999;137:134-43
Practical application of 3-dimensional echocardiography in evaluation of atrial septal defects (Mizelle and Sahn). 1999;137:1000-1
Prognosis of patients with vascular disease after clinical evaluation and dobutamine stress echocardiography (Ballal et al). 1999;137:469-75
Real-time, three-dimensional echocardiography: feasibility of dynamic right ventricular volume measurement with saline contrast (Ota et al). 1999;137:958-67
Secundum atrial septal defect is a dynamic three-dimensional entity (Dall'Agata et al). 1999;137:1175-81
Echocardiography, transesophageal
Clinical presentation, diagnosis, and hospital outcome of patients with documented aortic dissection: the Albany Medical Center experience, 1986 to 1996 (Torossov et al). 1999;137:154-61
Determinants of aortic artifacts during transesophageal echocardiography of the ascending aorta (Losi et al). 1999;137:968-73
Influence of gravity on pulmonary venous flow velocity patterns: analysis of left and right pulmonary venous flow velocities in left and right decubitus positions (Izumi et al). 1999;137:419-26
Transesophageal echocardiography and unexplained cerebral ischemia: a multicenter follow-up study (Labovitz). 1999;137:1082-1086
Editorials
Editorials. 1999;137:1-11, 187-215, 377-87, 577-602, 769-85, 996-9, 979-82, 983-4, 985-6, 987-8, 989-91, 992-5, 1000-1, 1002-4, 1007-9, 1010-1
Electric countershock
A comparison of 50-J versus 100-J shocks for direct-current cardioversion of atrial flutter (Pinski et al). 1999;137:439-42
Electrocardiography
Admission standard electrocardiogram for early risk stratification in patients with unstable coronary artery disease not eligible for acute revascularization therapy: a TRIM substudy (Holmvang et al). 1999;137:24-33
Clinical significance of syncope in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial (Olshansky et al). 1999;137:878-86
QT dispersion in athletic left ventricular hypertrophy (Mayet et al). 1999;137:678-81
QT dispersion in patients with Duchenne-type progressive muscular dystrophy (Yotsukura et al). 1999;137:672-7
ST-segment elevation during dobutamine stress testing predicts functional recovery after acute myocardial infarction (Piérard et al). 1999;137:500-11
ST-segment elevation after myocardial infarction: what does it mean and when is it useful? (Marwick). 1999;137:1002-4 (Editorial)
ST-segment elevation on Q leads at rest and during exercise: relation with myocardial viability and left ventricular remodeling within the first 6 months after infarction (Bodí et al). 1999;137:1107-15
Survival of DDD pacing mode after atrioventricular junction ablation and pacing for refractory atrial fibrillation (Wood et al). 1999;137:682-5
Value of ST-segment elevation pattern in predicting infarct size and left ventricular function at discharge in patients with reperfused acute anterior myocardial infarction (Kosuge et al). 1999;137:522-7
Electrocardiograpy, ambulatory
Diagnostic accuracy of ST changes detected by exercise testing and ambulatory electrocardiographic monitoring in apparently healthy individuals (Tzivoni and Butnaru). 1999;137:996-9 (Editorial)
ST-segment deviation during 24-hour ambulatory electrocar-

Electrocardiograpy, ambulatory—cont'd

diographic monitoring and exercise stress test in healthy male subjects 51 to 75 years of age: the Copenhagen City Heart Study (Vaage-Nilsen et al). 1999;137:1070-4

Electrophysiology

Clinical significance of syncope in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial (Olshansky et al). 1999;137:878-86

A comparison of 50-J versus 100-J shocks for direct-current cardioversion of atrial flutter (Pinski et al). 1999;137:439-42

Overdrive atrial pacing for conversion of atrial flutter: comparison of postoperative with nonpostoperative patients (Peters et al). 1999;137:100-3

QT dispersion in athletic left ventricular hypertrophy (Mayet et al). 1999;137:678-81

QT dispersion in patients with Duchenne-type progressive muscular dystrophy (Yotsukura et al). 1999;137:672-7

Recovery rates of regional sympathetic reinnervation and myocardial blood flow after acute myocardial infarction (Fallen et al). 1999;137:863-9

Relation between QT dispersion and slow intraventricular conduction in patients with acute anterior wall myocardial infarction (Mazur et al). 1999;137:104-8

Survival of DDD pacing mode after atrioventricular junction ablation and pacing for refractory atrial fibrillation (Wood et al). 1999;137:682-5

Underutilization of antithrombotic therapy in elderly rural patients with atrial fibrillation (Flaker et al). 1999;137:307-12

Use of intravenous adenosine as a noninvasive diagnostic test for sick sinus syndrome (Burnett et al). 1999;137:435-8

Embolism

Embolic risk based on aortic atherosclerotic morphologic features and aortic spontaneous echocardiographic contrast (Finkelhor et al). 1999;137:1088-93

Emergency medical services

Cardiac troponin T as a marker for myocardial ischemia in patients seen at the emergency department for active chest pain (Johnson et al). 1999;137:1137-44

Understanding true risk: evaluating troponins in the emergency setting (Gibler). 1999;137:985-6 (Editorial)

Enalapril

Different effects of enalapril and nitrendipine on the fibrinolytic system in essential hypertension (Sakata et al). 1999;137:1094-9

Enoximone

High-dose enoximone to evaluate reversibility of pulmonary hypertension: is there a diagnostic value of neurohormonal measurements? (Schulz et al). 1999;137:887-94

Equipment safety

Reuse of angioplasty catheters and risk of Creutzfeldt-Jakob disease (Fagih and Eisenberg). 1999;137:1173-8

Reuse of coronary catheters: old questions, new environment (Barbeau). 1999;137:1010-1 (Editorial)

Exercise

Comparison of the right and left ventricle as a systemic ventricle during exercise in patients with congenital heart disease (Ohuchi et al). 1999;137:1185-94

A neural link to explain the "muscle hypothesis" of exercise intolerance in chronic heart failure (Piepoli et al). 1999;137:1050-6

ST-segment elevation after myocardial infarction: what does it mean and when is it useful? (Marwick). 1999;137:1002-4 (Editorial)

ST-segment elevation on Q leads at rest and during exercise: relation with myocardial viability and left ventricular remodeling within the first 6 months after infarction (Bodí et al). 1999;137:1107-15

Exercise test

Diagnostic accuracy of ST changes detected by exercise testing and ambulatory electrocardiographic monitoring in apparently healthy individuals (Tzivoni and Butnaru). 1999;137:996-9 (Editorial)

Prognostic significance of double product and inadequate double product response to maximal symptom-limited exercise stress testing after myocardial infarction in 6296 patients treated with thrombolytic agents (Villella et al). 1999;137:443-52

ST-segment deviation during 24-hour ambulatory electrocardiographic monitoring and exercise stress test in healthy male subjects 51 to 75 years of age: the Copenhagen City Heart Study (Vaage-Nilsen et al). 1999;137:1070-4

Exercise tolerance

Cardiovascular responses to exercise in children and adolescents with myocardial dysfunction (Rowland et al). 1999;137:126-33

F

Felodipine

Antianginal efficacy of the combination of felodipine-metoprolol 10/100 mg compared with each drug alone in patients with stable effort-induced angina pectoris: a multicenter parallel group study (Emanuelsson et al). 1999;137:854-62

Fibrinolytic agents

Different effects of enalapril and nitrendipine on the fibrinolytic system in essential hypertension (Sakata et al). 1999;137:1094-9

Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens (Zeymer et al). 1999;137:34-8

Fibrinolytic therapy

The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy (Califf et al). 1999;137:S90-S93

Follow-up studies

Lone atrial fibrillation: prognostic differences between paroxysmal and chronic forms after 10 years of follow-up (Scardi et al). 1999;137:686-91

Long-term follow-up study of coronary reconstruction with multiple stents (Liu et al). 1999;137:292-7

Transesophageal echocardiography and unexplained cerebral ischemia: a multicenter follow-up study (Labovitz). 1999;137:1082-1086

Framingham Study

Association of left ventricular dilatation and hypertrophy with chronotropic incompetence in the Framingham Heart Study (Lauer et al). 1999;137:903-9

How generalizable are coronary risk prediction models? Comparison of Framingham and two national cohorts (Liao et al). 1999;137:837-45

Furosemide

Effects of short-acting and long-acting loop diuretics on heart rate variability in patients with chronic compensated congestive heart failure (Tomiyama et al). 1999;137:543-8

G

Genes

Influence of gene polymorphisms of the renin-angiotensin system on clinical outcome in heart failure among the Chinese (Sanderson et al). 1999;137:653-7

Growth hormone therapy

Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure (Giustina et al). 1999;137:1035-43

Growth hormone therapy in patients with congestive heart fail-

Growth hormone therapy—cont'd

ure: need for further research (Johnson and Gheorghiade). 1999;137:989-91 (Editorial)

H

Health policy

Economics and cost-effectiveness in evaluating the value of cardiovascular therapies: a health system perspective on thrombolytic therapy for acute myocardial infarction (Lewandowski and Kahler). 1999;137:S94-S96

Economic impact on physicians and hospitals of proposed changes in Medicare reimbursement for coronary interventions (Vaitkus). 1999;137:258-63

Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspective (Kessler). 1999;137:S111-S114

Terminology I would like to see disappear (Detsky). 1999;137:S51-S52

Variations in the use of cardiac procedures in the Veterans Health Administration (Mirvis and Graney). 1999;137:706-13

The value of cost-effectiveness analyses for reimbursement decisions: perspectives from Medicare (Sheingold). 1999;137:S81-S86

Variations in the use of cardiac procedures: what is the explanation? (Every and Ritchie). 1999;137:588-9 (Editorial)

What constitutes a useful economic study? The health systems perspective (Lee). 1999;137:S67-S70

Health resources

Economics and cost-effectiveness in evaluating the value of cardiovascular therapies: a health system perspective on thrombolytic therapy for acute myocardial infarction (Lewandowski and Kahler). 1999;137:S94-S96

Economic impact on physicians and hospitals of proposed changes in Medicare reimbursement for coronary interventions (Vaitkus). 1999;137:258-63

An industry perspective on health economics studies (Anderson et al). 1999;137:S129-S132

The value of cost-effectiveness analyses for reimbursement decisions: perspectives from Medicare (Sheingold). 1999;137:S81-S86

What constitutes a useful economic study? The health systems perspective (Lee). 1999;137:S67-S70

Heart catheterization

Cerebral microemboli during left heart catheterization (Fischer et al). 1999;137:162-8

Heart defects, congenital

Angiographic methods to assess human coronary angiogenesis (Gibson et al). 1999;137:169-79

Cerebral microemboli during left heart catheterization (Fischer et al). 1999;137:162-8

Characteristic cardiovascular manifestation in homozygous and heterozygous familial hypercholesterolemia (Kawaguchi et al). 1999;137:410-18

Comparison of the right and left ventricle as a systemic ventricle during exercise in patients with congenital heart disease (Ohuchi et al). 1999;137:1185-94

Heart failure

Epidemiology of myocardial infarction in France: therapeutic and prognostic implications of heart failure during the acute phase (Vaur et al). 1999;137:49-58

Mining gold standards from ivory towers: quality of care in academic medical centers (Konstam). 1999;137:987-8 (Editorial)

A neural link to explain the "muscle hypothesis" of exercise intolerance in chronic heart failure (Piepoli et al). 1999;137:1050-6

Quality of care for patients hospitalized with heart failure at academic medical centers (Nohria et al). 1999;137:1028-34

Heart failure, congestive

Abnormal course, abnormal flow, and systolic compression of the septal perforator associated with impaired myocardial perfusion in hypertrophic cardiomyopathy (Hiraski et al). 1999;137:109-17

Association of Killip class on admission and left ventricular dilatation after myocardial infarction: a closer look into an old clinical classification (Nešković et al). 1999;137:361-7

Congestive heart failure hospitalizations and survival in California: patterns according to race/ethnicity (Alexander et al). 1999;137:919-27

Diastolic dysfunction: old dog, new tricks (Douglas). 1999;137:777-8 (Editorial)

Effects of short-acting and long-acting loop diuretics on heart rate variability in patients with chronic compensated congestive heart failure (Tomiyama et al). 1999;137:543-8

Endothelin and von Willebrand factor as parameters of endothelial function in idiopathic dilated cardiomyopathy: different stimuli for release before and after heart transplantation? (Galatius et al). 1999;137:549-54

Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995 (Haldeman et al). 1999;137:352-60

Influence of gene polymorphisms of the renin-angiotensin system on clinical outcome in heart failure among the Chinese (Sanderson et al). 1999;137:653-7

Neurohumoral activations in congestive heart failure: correlations with cardiac function, heart rate variability, and baroreceptor sensitivity (Yoshikawa et al). 1999;137:666-71

Heart failure, congestive, drug therapy

ACE inhibitors in the management of congestive heart failure: comparative economic data (Boyko et al). 1999;137:S115-S119

Angiotensin-converting enzyme inhibitors in the management of congestive heart failure: a pharmaceutical industry perspective (Boccuzzi). 1999;137:S120-S122

Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction (Senior et al). 1999;137:646-52

High-dose enoximone to evaluate reversibility of pulmonary hypertension: is there a diagnostic value of neurohormonal measurements? (Schulz et al). 1999;137:887-94

Long-term β-blocker therapy improves autonomic nervous regulation in advanced congestive heart failure: a longitudinal heart rate variability study (Lin et al). 1999;137:658-65

Heart failure, congestive, therapy

Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure (Giustina et al). 1999;137:1035-43

Growth hormone therapy in patients with congestive heart failure: need for further research (Johnson and Gheorghiade). 1999;137:989-91 (Editorial)

Heart rate

Neurohumoral activations in congestive heart failure: correlations with cardiac function, heart rate variability, and baroreceptor sensitivity (Yoshikawa et al). 1999;137:666-71

Heart septal defects, atrial

Secundum atrial septal defect is a dynamic three-dimensional entity (Dall'Agata et al). 1999;137:1175-81

Heart transplantation

CA 125 and its relation to cardiac function (Nägele et al). 1999;137:1044-9

Endothelin and von Willebrand factor as parameters of endothelial function in idiopathic dilated cardiomyopathy: different stimuli for release before and after heart transplantation? (Galatius et al). 1999;137:549-54

Hypoplastic left heart syndrome: duration of survival without surgical intervention (Hoshino et al). 1999;137:535-42

Lung thallium imaging in coronary transplant arteriopathy: "Ce n'est pas un pipe" (Miller). 1999;137:782-5 (Editorial)

Prediction of human transplantation arteriopathy and coronary events with lung/heart count ratios during intravenous dipyridamole thallium-201 imaging (Lenihan et al). 1999;137:942-8

Heart valve prosthesis
Does pregnancy affect the durability of valvular bioprostheses? (Glower). 1999;137:590-1 (Editorial)
Effect of pregnancy on the duration of bovine pericardial bioprostheses (Salazar et al). 1999;137:714-20
Microbubbles associated with mechanical heart valves: their relation with serum lactic dehydrogenase levels (Gencbay et al). 1999;137:463-8
Thrombosis of bileaflet tricuspid valve prosthesis: clinical spectrum and the role of nonsurgical treatment (Shapira et al). 1999;137:721-5

Hemodynamics
Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure (Giustina et al). 1999;137:1035-43
Growth hormone therapy in patients with congestive heart failure: need for further research (Johnson and Gheorghiade). 1999;137:989-91 (Editorial)

Heparin
Bedside activated partial thromboplastin time monitoring: just a matter of time? (Patel and Moliterno). 1999;137:8-11 (Editorial)
Effectiveness of heparin in preventing thrombin generation and thrombin activity in patients undergoing coronary intervention (Ragosta et al). 1999;137:250-7
Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease (Toss et al). 1999; 137:72-9
A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease (Becker et al). 1999;137:59-71
Timely thrombolysis: synergism to open arteries and reduce mortality rates (Cannon). 1999;137:1-3 (Editorial)

Hospital costs
Economic impact on physicians and hospitals of proposed changes in Medicare reimbursement for coronary interventions (Vaitkus). 1999;137:258-63

Hospitalization
Congestive heart failure hospitalizations and survival in California: patterns according to race/ethnicity (Alexander et al). 1999;137:919-27
Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995 (Haldeman et al). 1999; 137:352-60
Mining gold standards from ivory towers: quality of care in academic medical centers (Konstam). 1999;137:987-8 (Editorial)
Quality of care for patients hospitalized with heart failure at academic medical centers (Nohria et al). 1999; 137:1028-34

Human immunodeficiency virus
Human immunodeficiency virus–associated pericardial effusion: report of 40 cases and review of the literature (Chen et al). 1999;137:516-21

Hypertension, pulmonary
High-dose enoximone to evaluate reversibility of pulmonary hypertension: is there a diagnostic value of neurohormonal measurements? (Schulz et al). 1999; 137:887-94

Hypertrophy, left ventricular
Association of left ventricular dilatation and hypertrophy with chronotropic incompetence in the Framingham Heart Study (Lauer et al). 1999;137:903-9
QT dispersion in athletic left ventricular hypertrophy (Mayet et al). 1999;137:678-81

Hypoplastic left heart syndrome
Hypoplastic left heart syndrome: duration of survival without surgical intervention (Hoshino et al). 1999;137:535-42

I

Image processing, computer assisted
Intravascular ultrasound and stent implantation: intraobserver and interobserver variability (Blessing et al). 1999;137:368-71
Nothin' but 'net? (Garratt). 1999;137:187-9 (Editorial)
Video networking of cardiac catheterization laboratories (Tobis et al). 1999;137:241-9

Infection
Chlamydia pneumoniae infection and atherosclerotic coronary disease (Sessa et al). 1999;137:1116-9
Infectious causes of atherosclerosis (Kuvin and Kimmelstiel). 1999;137:216-26

Infectious agents
Infectious causes of atherosclerosis (Kuvin and Kimmelstiel). 1999;137:216-26

Intra-aortic balloon pump
Hemodynamic effects of new intra-aortic balloon counterpulsation timing methods in patients: a multicenter evaluation (Kern et al). 1999;137:1129-36

K

Killip classification
Association of Killip class on admission and left ventricular dilatation after myocardial infarction: a closer look into an old clinical classification (Nešković et al). 1999; 137:361-7
The enduring value of Killip classification (Werns and Bates). 1999;137:213-15 (Editorial)

L

Language
The abbreviated life of acronyms (French and Ohman). 1999;137:577-8 (Editorial)
Acronyms of clinical trials in cardiology—1998 (Cheng). 1999;137:726-65
Terminology I would like to see disappear (Detsky). 1999; 137:S51-S52

Letters
Nitrate-stimulated tilt test (Aerts et al) (Letter); (Del Rosso and Bartoletti) (Reply). 1999;137:575-6
Predictability of left ventricular thrombus by mitral regurgitation (Sharma and McCullough) (Letter); (Kalaria) (Reply). 1999;137:373-4
Predictability of response rates, efficacy, risks, and intolerance with sotalol when used for sustained ventricular arrhythmias (Reiffel) (Letter); 1999;137:372
Significance of coronary flow reserve (Rother and Pfeiffer) (Letter); (Schulman) (Reply). 1999;137:766-8
Time-dependent changes of HRV after PTCA (Özcan et al) (Letter); (Osterhues) (Reply). 1999;137:375-6

Lidocaine
Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction (Sadowski et al). 1999;137:792-8
Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials (Alexander et al). 1999;137:799-805
Prophylactic lidocaine use in acute myocardial infarction revisited in the thrombolytic era (Tan and Lie). 1999;137:770-3 (Editorial)

Lipoproteins, LDL cholesterol
Comparative efficacy and tolerability of low-dose pravastatin versus lovastatin in patients with hypercholesterolemia (Strauss et al). 1999;137:458-62

Lovastatin
Comparative efficacy and tolerability of low-dose pravastatin

Lovastatin—cont'd

versus lovastatin in patients with hypercholesterolemia (Strauss et al). 1999;137:458-62

M

Magnetic resonance imaging
Paraplane analysis from precordial three-dimensional echocardiographic data sets for rapid and accurate quantification of left ventricular volume and function: a comparison with magnetic resonance imaging (Nosir et al). 1999;137:134-43
Managed care programs
A survey of standards and guidelines for cost-effectiveness analysis in health care (Stewart et al). 1999;137:S53-S61
Marfan syndrome
Effect of long-term β-blockade on aortic root compliance in patients with Marfan syndrome (Rios et al). 1999;137:1057-61
Medicare
Economic impact on physicians and hospitals of proposed changes in Medicare reimbursement for coronary interventions (Vaitkus). 1999;137:258-63
The value of cost-effectiveness analyses for reimbursement decisions: perspectives from Medicare (Sheingold). 1999;137:S81-S86
Metoprolol
Antianginal efficacy of the combination of felodipine-metoprolol 10/100 mg compared with each drug alone in patients with stable effort-induced angina pectoris: a multicenter parallel group study (Emanuelsson et al). 1999;137:854-62
Effect of intravenous metoprolol before hospital admission on chest pain in suspected acute myocardial infarction (Gardtman et al). 1999;137:821-9
Mitral valve insufficiency
Do cardiologists and general internists differ in testing and treating patients with aortic stenosis or mitral regurgitation? A preliminary study with editorial perspective (Alloggiamento et al). 1999;137:596-600 (Editorial)
Latent left ventricular dysfunction in patients with mitral regurgitation: feasibility of measuring diminished contractile reserve from a simplified model of noninvasively derived left ventricular pressure-volume loops (Leung et al). 1999;137:427-34
Predictability of left ventricular thrombus by mitral regurgitation (Sharma and McCullough) (Letter); (Kalaria) (Reply). 1999;137:373-4
Models
How generalizable are coronary risk prediction models? Comparison of Framingham and two national cohorts (Liao et al). 1999;137:837-45
Role of economic models in randomized clinical trials (Hlatky). 1999;137:S41-S46
Mortality
How generalizable are coronary risk prediction models? Comparison of Framingham and two national cohorts (Liao et al). 1999;137:837-45
Hypoplastic left heart syndrome: duration of survival without surgical intervention (Hoshino et al). 1999;137:535-42
Why is mortality rate after percutaneous transluminal coronary angioplasty higher in women? (Brodie). 1999;137:582-4 (Editorial)
Muscular dystrophy
Cardioprotection for Duchenne's muscular dystrophy (Ishikawa et al). 1999;137:895-902
QT dispersion in patients with Duchenne-type progressive muscular dystrophy (Yotsukura et al). 1999;137:672-7
Myocardial infarction
Coronary stent implantation in acute myocardial infarction (Mehta and Bates). 1999;137:603-11
Diagnostic performance of cardiac troponin I in suspected acute myocardial infarction: implications for clinicians (Tanasijevic and Antman). 1999;137:203-6 (Editorial)
Disparate effects of the 1989 Loma Prieta and 1994 Northridge earthquakes on hospital admissions for acute myocardial infarction: importance of superimposition of triggers (Brown). 1999;137:830-6
Disseminating the results of clinical trials to community-based practitioners: is anyone listening? (Goldberg and Gurwitz). 1999;137:4-7 (Editorial)
Early low-dose dobutamine echocardiography predicts late functional recovery after thrombolyzed acute myocardial infarction (Samad et al). 1999;137:489-93
Early referral for intentional rescue PTCA after initiation of thrombolytic therapy in patients admitted to a community hospital because of a large acute myocardial infarction (Ophuis et al). 1999;137:846-53
Epidemiology of myocardial infarction in France: therapeutic and prognostic implications of heart failure during the acute phase (Vaur et al). 1999;137:49-58
Infarct size: thrombolysis versus PTCA (Keeley and Weaver). 1999;137:1007-9 (Editorial)
Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens (Zeymer et al). 1999;137:34-8
Kinetics of tumor necrosis factor α in plasma and the cardioprotective effect of a monoclonal antibody to tumor necrosis factor α in acute myocardial infarction (Li et al). 1999;137:1145-52
Limitation of myocardial infarct size after primary angioplasty: is a higher patency the only mechanism? (Ottervanger et al). 1999;137:1169-72
Longitudinal changes and prognostic implications of left ventricular diastolic function in first acute myocardial infarction (Poulsen et al). 1999;137:910-18
Natural disaster plus wake-up time: a deadly combination of triggers (Kloner and Leor). 1999;137:779-81 (Editorial)
An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial) (Shapiro et al). 1999;137:1100-6
Prognostic significance of double product and inadequate double product response to maximal symptom-limited exercise stress testing after myocardial infarction in 6296 patients treated with thrombolytic agents (Villella et al). 1999;137:443-52
Prophylactic lidocaine use in acute myocardial infarction revisited in the thrombolytic era (Tan and Lie). 1999;137:770-3 (Editorial)
Recent aspirin use is associated with smaller myocardial infarct size and lower likelihood of Q-wave infarction (Mukamal et al). 1999;137:1120-8
Recovery rates of regional sympathetic reinnervation and myocardial blood flow after acute myocardial infarction (Fallen et al). 1999;137:863-9
Relation between QT dispersion and slow intraventricular conduction in patients with acute anterior wall myocardial infarction (Mazur et al). 1999;137:104-8
Smoking status and outcome after primary coronary angioplasty for acute myocardial infarction (Hasdai et al). 1999;137:612-20
Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: The MILIS-TIMI experience (Kizer et al). 1999;137:79-92
Value of ST-segment elevation pattern in predicting infarct size and left ventricular function at discharge in patients with reperfused acute anterior myocardial infarction (Kosuge et al). 1999;137:522-7
Myocardial infarction, complications
Should we emergently revascularize occluded coronaries for cardiogenic shock: an international randomized trial of emergency PTCA/CABG—trial design (Hochman et al). 1999;137:313-21

Myocardial infarction, complications—cont'd

Myocardial infarction, drug therapy
Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction (Senior et al). 1999;137:646-52
Effect of intravenous metoprolol before hospital admission on chest pain in suspected acute myocardial infarction (Gardtman et al). 1999;137:821-9
Implementation of serum cardiac troponin I as the marker for detection of acute myocardial infarction (Falahati et al). 1999;137:332-7
Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction (Sadowski et al). 1999;137:792-8
Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials (Alexander et al). 1999;137:799-805

Myocardial infarction, prevention and control
Effect of intravenous metoprolol before hospital admission on chest pain in suspected acute myocardial infarction (Gardtman et al). 1999;137:821-9
Secondary prevention of myocardial infarction: role of β-adrenergic blockers and angiotensin-converting enzyme inhibitors (Frishman and Cheng). 1999;137:S25-S34

Myocardial infarction, therapy
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies: a health system perspective on thrombolytic therapy for acute myocardial infarction (Lewandowski and Kahler). 1999;137:S94-S96

Myocardial ischemia
Cardiac risk: theme con variations (Willich). 1999;137:384-5 (Editorial)
Cardiac troponin T as a marker for myocardial ischemia in patients seen at the emergency department for active chest pain (Johnson et al). 1999;137:1137-44
Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial (Thel et al). 1999;137:264-73
Extracardiac contributions to chest pain perception in patients 6 months after acute myocardial infarction (Ladwig et al). 1999;137:528-34
Human immunodeficiency virus–associated pericardial effusion: report of 40 cases and review of the literature (Chen et al). 1999;137:516-21
Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial (Van de Werf et al). 1999;137:786-91
Value of ST-segment elevation pattern in predicting infarct size and left ventricular function at discharge in patients with reperfused acute anterior myocardial infarction (Kosuge et al). 1999;137:522-7
Weekly and seasonal variation in the incidence of cardiac arrests (Peckova et al). 1999;137:512-15

Myocardial ischemia, diagnosis
Clinical predictors of in-hospital prognosis in unstable angina: ECLA 3 (Bazzino et al). 1999;137:322-31
Diagnosis, incidence, and clinical significance of early postoperative ischemia after transmyocardial laser revascularization (Hughes et al). 1999;137:1163-8
Should we emergently revascularize occluded coronaries for cardiogenic shock: an international randomized trial of emergency PTCA/CABG—trial design (Hochman et al). 1999;137:313-21
ST-segment elevation during dobutamine stress testing predicts functional recovery after acute myocardial infarction (Piérard et al). 1999;137:500-11
Understanding true risk: evaluating troponins in the emergency setting (Gibler). 1999;137:985-6 (Editorial)

Myocardial ischemia, drug therapy
Implementation of serum cardiac troponin I as the marker for detection of acute myocardial infarction (Falahati et al). 1999;137:332-7

Myocardial ischemia, physiopathology
C-reactive protein and coronary artery disease: additional evidence of the implication of an inflammatory process in acute coronary syndromes (Abdelmouttaleb et al). 1999;0137:346-51
Lower thrombolytic use for African Americans with myocardial infarction: an influence of clinical presentation? (Borzak et al). 1999;137:338-45

Myocardial revascularization
Diagnosis, incidence, and clinical significance of early postoperative ischemia after transmyocardial laser revascularization (Hughes et al). 1999;137:1163-8
Patient preferences in coronary revascularization (Hornberger et al). 1999;137:1153-62
Use of abciximab: comparative economic data (Mark and Simons). 1999;137:S123-S125
What kind of coronary revascularization does the average American really want? (Oz). 1999;137:1005-6

N

Necrosis
Kinetics of tumor necrosis factor α in plasma and the cardioprotective effect of a monoclonal antibody to tumor necrosis factor α in acute myocardial infarction (Li et al). 1999;137:1145-52
Myocardial necrosis in "pure unstable angina": identification of high-risk subgroups or a contradiction in terms? (Jesse). 1999;137:190-2 (Editorial)

Neurosecretory systems
High-dose enoximone to evaluate reversibility of pulmonary hypertension: is there a diagnostic value of neurohormonal measurements? (Schulz et al). 1999;137:887-94
Neurohumoral activations in congestive heart failure: correlations with cardiac function, heart rate variability, and baroreceptor sensitivity (Yoshikawa et al). 1999;137:666-71

Nitrates
Nitrate-stimulated tilt test (Aerts et al) (Letter); (Del Rosso and Bartoletti) (Reply). 1999;137:575-6

Nitrendipine
Different effects of enalapril and nitrendipine on the fibrinolytic system in essential hypertension (Sakata et al). 1999;137:1094-9

O

Outcome assessment
Association of Killip class on admission and left ventricular dilatation after myocardial infarction: a closer look into an old clinical classification (Nešković et al). 1999;137:361-7
Bailout coronary stenting: not always a foolproof safety net (de Feyter). 1999;137:579-81 (Editorial)
Cause of in-hospital death in 12,232 consecutive patients undergoing percutaneous transluminal coronary angioplasty (Malenka et al). 1999;137:632-8
Clinical predictors of in-hospital prognosis in unstable angina: ECLA 3 (Bazzino et al). 1999;137:322-31
Clinical presentation, diagnosis, and hospital outcome of patients with documented aortic dissection: the Albany Medical Center experience, 1986 to 1996 (Torossov et al). 1999;137:154-61
Hospitalization of patients with heart failure: National Hospital

Outcome assessment—cont'd

Discharge Survey, 1985 to 1995 (Haldeman et al). 1999; 137:352-60
Human immunodeficiency virus–associated pericardial effusion: report of 40 cases and review of the literature (Chen et al). 1999;137:516-21
The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy (Califf et al). 1999;137:S90-S93
Improving outcomes of percutaneous coronary intervention (Nash). 1999;137:979-82 (Editorial)
Influence of gene polymorphisms of the renin-angiotensin system on clinical outcome in heart failure among the Chinese (Sanderson et al). 1999;137:653-7
Lone atrial fibrillation: epidemiology and natural history (Gersh and Solomon). 1999;137:592-5 (Editorial)
Lone atrial fibrillation: prognostic differences between paroxysmal and chronic forms after 10 years of follow-up (Scardi et al). 1999;137:686-91
Pathology of bailout coronary stenting in human beings (Farb et al). 1999;137:621-31
Patient preferences in coronary revascularization (Hornberger et al). 1999;137:1153-62
Percutaneous transluminal coronary angioplasty in the elderly: epidemiology, clinical risk factors, and in-hospital outcomes (Wennberg et al). 1999;137:639-45
Physical examination in valvular aortic stenosis: correlation with stenosis severity and prediction of clinical outcome (Munt et al). 1999;137:298-306
Prognostic significance of double product and inadequate double product response to maximal symptom-limited exercise stress testing after myocardial infarction in 6296 patients treated with thrombolytic agents (Villella et al). 1999; 137:443-52
Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials (Alexander et al). 1999;137:799-805
Smoking status and outcome after primary coronary angioplasty for acute myocardial infarction (Hasdai et al). 1999; 137:612-20
Trends in clinical and economic outcomes of coronary angioplasty from 1992 to 1995: a population-based analysis (Cohen et al). 1999;137:1012-8
Variations in the use of cardiac procedures in the Veterans Health Administration (Mirvis and Graney). 1999; 137:706-13
Variations in the use of cardiac procedures: what is the explanation? (Every and Ritchie). 1999;137:588-9 (Editorial)

P

Pain

Effect of intravenous metoprolol before hospital admission on chest pain in suspected acute myocardial infarction (Gardtman et al). 1999;137:821-9
Extracardiac contributions to chest pain perception in patients 6 months after acute myocardial infarction (Ladwig et al). 1999;137:528-34

Perfusion

Abnormal course, abnormal flow, and systolic compression of the septal perforator associated with impaired myocardial perfusion in hypertrophic cardiomyopathy (Hiraski et al). 1999;137:109-17

Pharmaceutical industry

Angiotensin-converting enzyme inhibitors in the management of congestive heart failure: a pharmaceutical industry perspective (Boccuzzi). 1999;137:S120-S122
An industry perspective on health economics studies (Anderson et al). 1999;137:S129-S132
Product labeling and pharmacoeconomic information (Morris). 1999;137:S78-S80
What constitutes a useful health economic study for the pharmaceutical industry? (Gagnon). 1999;137:S62-S66

Physical examination

Physical examination in valvular aortic stenosis: correlation with stenosis severity and prediction of clinical outcome (Munt et al). 1999;137:298-306

Plasma

Kinetics of tumor necrosis factor α in plasma and the cardioprotective effect of a monoclonal antibody to tumor necrosis factor α in acute myocardial infarction (Li et al). 1999;137:1145-52

Plasminogen

Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial (Van de Werf et al). 1999;137:786-91

Platelet membrane glycoproteins

Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty (Haase et al). 1999;137:234-40
Health system perspective regarding glycoprotein IIb/IIIa inhibitor therapy (Schrogie). 1999;137:S126-S128
Use of abciximab: comparative economic data (Mark and Simons). 1999;137:S123-S125

Polymorphism

Angiotensinogen M235T polymorphism is associated with plasma angiotensinogen and cardiovascular disease (Winkelmann et al). 1999;137:698-705

Postmenopause

Impaired forearm blood flow and vasodilator reserve in healthy postmenopausal women (Mercuro et al). 1999; 137:692-7

Postoperative care

Diagnosis, incidence, and clinical significance of early postoperative ischemia after transmyocardial laser revascularization (Hughes et al). 1999;137:1163-8

Posture

Influence of gravity on pulmonary venous flow velocity patterns: analysis of left and right pulmonary venous flow velocities in left and right decubitus positions (Izumi et al). 1999;137:419-26

Pravastatin

Comparative efficacy and tolerability of low-dose pravastatin versus lovastatin in patients with hypercholesterolemia (Strauss et al). 1999;137:458-62

Pregnancy

Does pregnancy affect the durability of valvular bioprostheses? (Glower). 1999;137:590-1 (Editorial)
Effect of pregnancy on the duration of bovine pericardial bioprostheses (Salazar et al). 1999;137:714-20

Preventive health services

Efficacy and tolerability of tasosartan, a novel angiotensin II receptor blocker: results from a 10-week, double-blind, placebo-controlled, dose-titration study (Neutel et al). 1999;137:118-25
Session highlights from the European Society of Cardiology XXth Annual Congress: August 22 to 26, 1998 (Alexander and Kong). 1999;137:180-6

Progress in cardiology

Progress in cardiology. 1999;137:388-409

Q

Quality of care

Mining gold standards from ivory towers: quality of care in academic medical centers (Konstam). 1999;137:987-8 (Editorial)
Quality of care for patients hospitalized with heart failure at

Quality of care—cont'd

academic medical centers (Nohria et al). 1999;137:1028-34

R

Racial factors
Congestive heart failure hospitalizations and survival in California: patterns according to race/ethnicity (Alexander et al). 1999;137:919-27
Influence of gene polymorphisms of the renin-angiotensin system on clinical outcome in heart failure among the Chinese (Sanderson et al). 1999;137:653-7
Lower thrombolytic use for African Americans with myocardial infarction: an influence of clinical presentation? (Borzak et al). 1999;137:338-45
Understanding racial differences in the use of thrombolytic therapy: what more do we need to know? (Maynard). 1999;137:211-12 (Editorial)

Remodeling
ST-segment elevation after myocardial infarction: what does it mean and when is it useful? (Marwick). 1999;137:1002-4 (Editorial)
ST-segment elevation on Q leads at rest and during exercise: relation with myocardial viability and left ventricular remodeling within the first 6 months after infarction (Bodí et al). 1999;137:1107-5

Restenosis
Infectious causes of atherosclerosis (Kuvin and Kimmelstiel). 1999;137:216-26

Risk factors
Admission standard electrocardiogram for early risk stratification in patients with unstable coronary artery disease not eligible for acute revascularization therapy: a TRIM substudy (Holmvang et al). 1999;137:24-33
How generalizable are coronary risk prediction models? Comparison of Framingham and two national cohorts (Liao et al). 1999;137:837-45
Rationale and design of the Prospective Army Coronary Calcium (PACC) Study: utility of electron beam computed tomography as a screening test for coronary artery disease and as an intervention for risk factor modification among young, asymptomatic, active-duty United States Army personnel (O'Malley et al). 1999;137:932-41

S

Sertraline
An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial) (Shapiro et al). 1999;137:1100-6

Sex factors
Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease (Toss et al). 1999;137:72-9

Sick sinus syndrome
Is an adenosine challenge a useful test for diagnosing sick sinus syndrome? (Sorrentino). 1999;137: 377-80 (Editorial)
Use of intravenous adenosine as a noninvasive diagnostic test for sick sinus syndrome (Burnett et al). 1999;137:435-8

Smoking
Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease (Toss et al). 1999;137:72-9
Relation of salivary cotinine to blood pressure in middle-aged cigarette smokers (Istvan et al). 1999;137:928-31
Smoking status and outcome after primary coronary angioplasty for acute myocardial infarction (Hasdai et al). 1999; 137:612-20

Sotalol
Predictability of left ventricular thrombus by mitral regurgitation (Sharma and McCullough) (Letter); (Kalaria) (Reply). 1999;137:373-4
Sotalol: an important new antiarrhythmic (Anderson and Prystowsky). 1999;137: 388-409 (Prog. cardiol.)

Sports
QT dispersion in athletic left ventricular hypertrophy (Mayet et al). 1999;137:678-81

Stents
Bailout coronary stenting: not always a foolproof safety net (de Feyter). 1999;137:579-81 (Editorial)
Clinical implications of intravascular ultrasound imaging for stenting procedures (Bruining et al). 1999;137:207-10 (Editorial)
Coronary stent implantation in acute myocardial infarction (Mehta and Bates). 1999;137:603-11
Coronary stents: a health system perspective (Ahmad). 1999;137:S142-S144
Coronary stents: an industry perspective (Marshall). 1999;137:S138-S141
Evaluation of the cost-effectiveness of coronary stenting: a societal perspective (Cohen). 1999;137:S133-137
Impact of target lesion calcification on coronary stent expansion after rotational atherectomy (Henneke et al). 1999; 137:93-9
Intravascular ultrasound and stent implantation: intraobserver and interobserver variability (Blessing et al). 1999; 137:368-71
Long-term follow-up study of coronary reconstruction with multiple stents (Liu et al). 1999;137:292-7
Pathology of bailout coronary stenting in human beings (Farb et al). 1999;137:621-31
Treatment of diffuse coronary lesions: a time for randomized trials (Cohen and Dauerman). 1999;137:193-5 (Editorial)

Stress, psychological
Circadian variation and triggering of acute coronary events (Muller). 1999;137:S1-S8
Disparate effects of the 1989 Loma Prieta and 1994 Northridge earthquakes on hospital admissions for acute myocardial infarction: importance of superimposition of triggers (Brown). 1999;137:830-6
Natural disaster plus wake-up time: a deadly combination of triggers (Kloner and Leor). 1999;137:779-81 (Editorial)

Sympathetic nervous system
Recovery rates of regional sympathetic reinnervation and myocardial blood flow after acute myocardial infarction (Fallen et al). 1999;137:863-9

Syncope
Clinical significance of syncope in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial (Olshansky et al). 1999;137:878-86
The high cost of syncope: cost implications of a new insertable loop recorder in the investigation of recurrent syncope (Krahn et al). 1999;137:870-7

T

Thallium
Lung thallium imaging in coronary transplant arteriopathy: "Ce n'est pas un pipe" (Miller). 1999;137:782-5 (Editorial)
Prediction of human transplantation arteriopathy and coronary events with lung/heart count ratios during intravenous

dipyridamole thallium-201 imaging (Lenihan et al). 1999; 137:942-8

Thrombin

Effectiveness of heparin in preventing thrombin generation and thrombin activity in patients undergoing coronary intervention (Ragosta et al). 1999;137:250-7

Much ado about thrombin (Kleiman). 1999;137:196-8 (Editorial)

Thromboembolism

A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease (Becker et al). 1999;137:59-71

Thrombolysis in Myocardial Infarction Investigators

Methodologic drift in the assessment of TIMI grade 3 flow and its implications with respect to the reporting of angiographic trial results (Gibson et al). 1999;137:1179-84

Thrombolytic therapy

Early referral for intentional rescue PTCA after initiation of thrombolytic therapy in patients admitted to a community hospital because of a large acute myocardial infarction (Ophuis et al). 1999;137:846-53

Economics and cost-effectiveness in evaluating the value of cardiovascular therapies: a health system perspective on thrombolytic therapy for acute myocardial infarction (Lewandowski and Kahler). 1999;137:S94-S96

Infarct size: thrombolysis versus PTCA (Keeley and Weaver). 1999;137:1007-9 (Editorial)

Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens (Zeymer et al). 1999;137:34-8

Limitation of myocardial infarct size after primary angioplasty: is a higher patency the only mechanism? (Ottervanger et al). 1999;137:1169-72

Lower thrombolytic use for African Americans with myocardial infarction: an influence of clinical presentation? (Borzak et al). 1999;137:338-45

Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial (Van de Werf et al). 1999; 137:786-91

Thrombolytic therapy: economic considerations (Krumholz). 1999;137:S87-S89

Timely thrombolysis: synergism to open arteries and reduce mortality rates (Cannon). 1999;137:1-3 (Editorial)

Understanding racial differences in the use of thrombolytic therapy: what more do we need to know? (Maynard). 1999;137:211-12 (Editorial)

Thrombosis

Systemic and translesional activation of coagulation, fibrinolytic, and inhibitory systems in candidates for coronary angioplasty: basal state and effect of successful dilation (Lehmann et al). 1999;137:274-83

Thrombosis of bileaflet tricuspid valve prosthesis: clinical spectrum and the role of nonsurgical treatment (Shapira et al). 1999;137:721-5

Tilt test

Nitrate-stimulated tilt test (Aerts et al) (Letter); (Del Rosso and Bartoletti) (Reply). 1999;137:575-6

Transmyocardial laser revascularization

Diagnosis, incidence, and clinical significance of early postoperative ischemia after transmyocardial laser revascularization (Hughes et al). 1999;137:1163-8

Troponin

Cardiac troponin T as a marker for myocardial ischemia in patients seen at the emergency department for active chest pain (Johnson et al). 1999;137:1137-44

Diagnostic performance of cardiac troponin I in suspected acute myocardial infarction: implications for clinicians (Tanasijevic and Antman). 1999;137:203-6 (Editorial)

Direct comparison of early elevations of cardiac troponin T and I in patients with clinical unstable angina (Ottani et al). 1999;137:284-91

Elevated cardiac troponin I predicts a high-risk angiographic anatomy of the culprit lesion in unstable angina (Benamer et al). 1999;137:815-20

Implementation of serum cardiac troponin I as the marker for detection of acute myocardial infarction (Falahati et al). 1999;137:332-7

Understanding true risk: evaluating troponins in the emergency setting (Gibler). 1999;137:985-6 (Editorial)

U

Ultrasonography, interventional

Angle dependence of intravascular ultrasound imaging and its feasibility in tissue characterization of human atherosclerotic tissue (Hiro et al). 1999;137:476-81

Calcified plaque cross-sectional area in human arteries: correlation between intravascular ultrasound and undecalcified histology (Kostamaa et al). 1999;137:482-8

Clinical implications of intravascular ultrasound imaging for stenting procedures (Bruining et al). 1999;137:207-10 (Editorial)

Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial (Thel et al). 1999;137:264-73

Effectiveness of heparin in preventing thrombin generation and thrombin activity in patients undergoing coronary intervention (Ragosta et al). 1999;137:250-7

Intravascular ultrasound and stent implantation: intraobserver and interobserver variability (Blessing et al). 1999; 137:368-71

Nothin' but 'net? (Garratt). 1999;137:187-9 (Editorial)

United States Food and Drug Administration

Product labeling and pharmacoeconomic information (Morris). 1999;137:S78-S80

Role of government agencies regarding cost-effectiveness claims: FDA perspective (Temple). 1999;137:S75-S77

V

Valvular heart disease

Echocardiographic evaluation of patients with primary antiphospholipid syndrome (Espínola-Zavaleta et al). 1999;137:974-9

Physical examination in valvular aortic stenosis: correlation with stenosis severity and prediction of clinical outcome (Munt et al). 1999;137:298-306

Vasodilation

Impaired forearm blood flow and vasodilator reserve in healthy postmenopausal women (Mercuro et al). 1999;137:692-7

Ventricular function, left

Association of Killip class on admission and left ventricular dilatation after myocardial infarction: a closer look into an old clinical classification (Nešković et al). 1999;137:361-7

Association of left ventricular dilatation and hypertrophy with chronotropic incompetence in the Framingham Heart Study (Lauer et al). 1999;137:903-9

Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction (Senior et al). 1999;137:646-52

Comparison of the right and left ventricle as a systemic ventricle during exercise in patients with congenital heart disease (Ohuchi et al). 1999;137:1185-94

The enduring value of Killip classification (Werns and Bates). 1999;137:213-15 (Editorial)

Ventricular function, left—cont'd

Longitudinal changes and prognostic implications of left ventricular diastolic function in first acute myocardial infarction (Poulsen et al). 1999;137:910-18

ST-segment elevation on Q leads at rest and during exercise: relation with myocardial viability and left ventricular remodeling within the first 6 months after infarction (Bodí et al). 1999;137:1107-5

Ventricular function, right

Comparison of the right and left ventricle as a systemic ventricle during exercise in patients with congenital heart disease (Ohuchi et al). 1999;137:1185-94

Real-time, three-dimensional echocardiography: feasibility of dynamic right ventricular volume measurement with saline contrast (Ota et al). 1999;137:958-67

W

Women

Diagnosis of suspected coronary artery disease in women: a cost-effectiveness analysis (Kim et al). 1999;137:1019-27

Diagnostic testing for coronary heart disease in women: new information generates new questions (Wenger). 1999;137:983-4 (Editorial)

Does pregnancy affect the durability of valvular bioprostheses? (Glower). 1999;137:590-1 (Editorial)

Impaired forearm blood flow and vasodilator reserve in healthy postmenopausal women (Mercuro et al). 1999; 137:692-7

Why is mortality rate after percutaneous transluminal coronary angioplasty higher in women? (Brodie). 1999;137:582-4 (Editorial)